**Chapter: Cancer: Unveiling its complexity from genetic aberrations to personalized therapies.**

**Author: Kalash Mangtani**

**Dr. B. Lal Institute of Biotechnology**

**Malviya Industrial Area, Malviya Nagar, Jaipur**

**E-mail:** **kalashmangtani@gmail.com** **,** **kalash13mangtani@gmail.com**

**Phone No.**: **9468900104**

**Abstract**

In the realm of cancer research and treatment, understanding the intricate interplay between genetic aberrations and personalized therapies is of paramount importance. This chapter delves into the intricate world of cancer, dissecting its diverse facets from genetic mutations to therapeutic advancements. It dissects the molecular drivers behind cancer initiation, progression, and metastasis, elucidating the role of tumor microenvironments. Focusing on treatment, the chapter explores established modalities, like chemotherapy, and highlights the transformative potential of targeted therapies, immunotherapies, and precision medicine. Through case studies and emerging trends, it underscores the evolution of cancer research and its translation into an innovative patient-centric approaches.

1. **Introduction**

Picture our body as a bustling city, where cells are the diligent citizens following a set of rules – regulated division, differentiation, and a sense of when it's time to gracefully step aside through apoptosis, a natural form of cell death. It's a symphony of growth, change, and renewal that keeps our body in harmony. But what happens when these once-obedient cells lose their way? That's where the story of cancer begins.

Amid the hustle and bustle of this cellular megacity, certain cells start to behave differently. They no longer listen to the familiar tune of regulated division, differentiation, and apoptosis. Instead, they go rogue, growing uncontrollably and refusing to fade away. This transformation marks the birth of tumor cells – a disruptive force that challenges the balance and harmony our body strives to maintain.

In this chapter, we embark on an illuminating journey to uncover the complications of this cellular revolution. From the genetic switches that go haywire to the molecular dances that fuel uncontrolled growth, we'll dissect the transformation from normalcy to tumorigenesis. But our exploration will not stop there. Researchers are also trying to discover the remarkable tools that science and medicine wield in the battle against these unruly cells.

Imagine a battlefield where precision is key – where treatments are tailored to the unique traits of each tumor. We'll delve into the arsenal of targeted therapies and groundbreaking technologies that stand as the modern weapons against cancer. Beyond the scientific frontier, we'll meet the heroes of this struggle – the patients, families, and healthcare warriors who face cancer with unwavering courage.

So, fasten your seatbelts as we journey into the realm of cancer. From the intricate dance of genes to the promise of personalized medicine, our exploration is guided by curiosity and fueled by hope. As we navigate the twists and turns of this cellular narrative, we march toward a future where the power of cancer is tamed and the light of healing shines ever brighter.

1. **Definition**

A normal cell undergoes controlled division, differentiation, and programmed cell death (apoptosis). When these normal cells have lost the customary regulation of their division, differentiation, and apoptosis, they transform into **tumor cells** [1]. These rogue cells, often forming masses known as **tumors**, disrupt the normal functions of tissues and organs. Cancer cells can invade nearby tissues and, in some cases, spread to other parts of the body through a process called **metastasis**. Metastasis stands out as the foremost life-threatening occurrence for individuals with cancer. This intricate process entails a series of sequential events that must transpire for tumor cells to accomplish successful metastasis—a phenomenon referred to as the metastatic cascade [2]. This process significantly adds to the intricate nature of cancer as a multifaceted ailment. Within the metastatic cascade, alterations in cell-cell and cell-matrix adhesion assume a position of paramount significance [3]. The intricate interplay of genetic mutations, environmental factors, and cellular dynamics contributes to the development of cancer, making it a multifaceted challenge that impacts millions of lives worldwide.

1. **History**

The existence of cancer predates the emergence of humans [4]. Fossil records and studies of ancient remains have revealed signs of cancer in various species that lived long before humans appeared on Earth. This evidence suggests that cancer is not exclusive to humans but has been a part of the natural world for a significant span of time [5]. The etymology of the term "cancer" can be traced back to the pioneering work of ancient Greek and Roman physicians. The Greek physician **Hippocrates** (460-370 BC), often referred to as the "Father of Medicine," is credited with coining the terms "*carcinos*" and "*carcinoma*” to describe tumors that do not ulcerate and those that do [4, 6]. The Latin word "*cancer*," which translates to "crab," was later applied by the Roman physician **Celsus** (25 BC - 50 AD) to capture the finger-like projections of cancerous growths that brought to mind the shape of a crab. **Galen** (130-200 AD), another prominent Greek physician, introduced the term "*oncos*" (Greek for swelling) to characterize tumors [7]. The enduring use of the crab analogy from the days of Hippocrates and Celsus to depict malignant tumors highlights their lasting impact on medical terminology. Furthermore, Galen's term "*oncos*" has found a contemporary resonance as an integral part of the word "oncologist," denoting specialists dedicated to the study and treatment of cancer. This etymological journey underscores the intricate evolution of medical language, reflecting the observations and insights of early medical practitioners.

1. **Benign and Malignant Tumors**

A tumor, also referred to as a **neoplasm**, is an abnormal mass of cells within the body [8]. This anomalous growth arises from cells dividing excessively or evading their natural cell death processes. Tumors can stem from various factors including genetic mutations and environmental triggers.

Tumors are broadly categorized as either benign or malignant.

* 1. **Benign Tumors**

Benign tumors are non-cancerous growths that usually do not extend to other parts of the body. Benign tumors are characterized by their tendency to remain localized in their original site, refraining from infiltrating other areas of the body [1, 9]. They lack the capacity to spread to adjacent structures or distant regions. Typically, benign tumors exhibit gradual growth patterns and well-defined boundaries.

Although benign tumors are generally non-disruptive (do not invade nearby tissues or spread to other parts of the body), they can expand significantly and exert pressure on nearby structures, leading to discomfort or medical complications. For instance, a sizable benign lung tumor could compress the trachea (windpipe), resulting in breathing difficulties. In such cases, prompt surgical intervention becomes essential. Importantly, the likelihood of recurrence after removal of benign tumors is low. Examples of benign tumors encompass fibroids within the uterus and lipomas in the skin.

Certain specific types of benign tumors carry the potential to transform into malignant tumors. Vigilant monitoring is crucial in these instances, and surgical removal may be recommended. For instance, colon polyps, which represent abnormal cell masses, hold the potential to evolve into malignancies. Consequently, they are typically subjected to surgical excision to pre-empt such a progression.

* 1. **Malignant Tumors (Cancer)**

Malignant tumors are characterized by their cells undergoing uncontrolled growth and exhibiting the ability to spread both within their local vicinity and to distant locations. These tumors are cancerous in nature, displaying the capacity to invade surrounding sites [1]. They utilize the bloodstream or the lymphatic system as pathways to disseminate to remote areas. This process of widespread dissemination is known as ‘*metastasis’* [10]. Metastasis has the potential to manifest in any part of the body, with prevalent occurrences observed in organs such as the liver, lungs, brain, and bones. Malignant neoplastic cells often display anaplastic features (characterized by a deficiency in cellular differentiation, termed anaplasia) or are notably less differentiated than the healthy cells of the originating tissue [11]. Conversely, benign tumor cells exhibit well-differentiated characteristics and present an appearance of normalcy.

**Table 1: Comparison between benign and malignant tumors.**

|  |  |  |  |
| --- | --- | --- | --- |
| Characteristics | Malignant Tumor | Benign Tumor | References |
| Rate of Growth | Rapid | Slow  | [9] |
| Differentiation  | Lacks Differentiation | Well Differentiated  | [12] |
| Invasiveness  | Present  | Absent  | [13] |
| Metastasis  | Present  | Absent (Stay Localized) | [9] |
| Shape  | Nodular / Stellate/ Irregular | Smooth/ oval / lobulated/ regular. | [14] |
| Manner of Growth | Infiltrative, non-encapsulated, destroys adjacent tissues. | Expansile, often encapsulated, displaces nearby tissues. | [15] |

1. **Classification and Origin**

Benign and malignant tumors are categorized based on the specific cell lineage from which they originate. Tumor classification involves dividing them into four primary groups according to their cellular source: **epithelial**, **mesenchymal**, **hematopoietic**, and **neuroectodermal**. Within each broad category, numerous subgroups exist, further delineated by factors such as the tumor's distinct cellular type, its anatomical location within the body, and its microscopic characteristics.

* 1. **Cancer of Epithelial Origin**

Epithelial cancers also referred to as **carcinomas**, comprise approximately 90% of all cancer cases [1]. These cancers originate from cells that form the epithelial tissue, which lines various organs and surfaces of the body. Epithelial tissues play crucial roles in protection, absorption, and secretion.

Carcinomas can be further classified into subtypes based on the type of epithelial cell from which they originate. For example, adenocarcinomas arise from glandular epithelial cells that produce fluids or mucous, while squamous cell carcinomas develop from squamous epithelial cells that form the skin's outer layer and line certain internal organs [16].

The diverse locations where epithelial cancers can develop contribute to their varied clinical presentations and outcomes. Some common examples of epithelial cancers include lung adenocarcinoma, breast carcinoma, colon adenocarcinoma, and squamous cell carcinoma of the skin (Table 2).

* 1. **Cancer of Mesenchymal origin**

Cancers of mesenchymal origin, known as **sarcomas**, arise from cells that belong to the mesenchymal tissue [14, 17, 18]. Mesenchymal tissues include connective tissues such as bone, cartilage, muscle and blood vessels [18]. Sarcomas account for a smaller proportion of overall cancer cases compared to carcinomas (epithelial cancers), but they represent a diverse group of malignancies with unique characteristics [1].

Sarcomas can be further categorized into various subtypes based on the specific type of mesenchymal cell they originate from. For instance, osteosarcoma arises from bone-forming cells, chondrosarcoma from cartilage cells, and liposarcoma from fat cells [19]. (Table 2)

* 1. **Cancer of Hematopoietic origin**

Cancers of hematopoietic origin, commonly referred to as hematologic malignancies or blood cancers, arise from cells within the hematopoietic system, which is responsible for the formation of blood cells. These cancers affect the production and function of blood cells and can be broadly categorized into three main types:

* **Leukemia:** Leukemia are cancers that originate in the bone marrow and affect the production of white blood cells [20]. They can be acute (rapidly progressing) or chronic (slowly progressing) and are further classified based on the type of white blood cell affected—lymphoblastic or myeloid. Leukemia can crowd out normal blood cells, leading to anemia, infection, and bleeding [21].
* **Lymphoma:** Lymphomas are cancers that develop in the lymphatic system, which includes lymph nodes, lymphatic vessels, and organs like the spleen and thymus. They are broadly categorized into two main types: **Hodgkin lymphoma** and **non-Hodgkin lymphoma** [22]. Hodgkin Lymphoma is relatively rare, constituting around 10% of lymphoma cases. It is characterized by distinctive Reed-Sternberg cells and typically begins in a single lymph node or chain, often peaking in young and older adults. When these cells present as single-nucleated entities, they are referred to as **Hodgkin cells**. However, when they take on a multinucleated form, they are termed **Reed-Sternberg cells**. The presence and characteristics of Hodgkin and Reed-Sternberg cells play a pivotal role in diagnosing and understanding the disease's progression [23]. On the other hand, non-Hodgkin Lymphoma is more common and encompasses various lymphoma types originating from different lymphocytes. It can be indolent or aggressive, involve diverse tissues, and is linked to factors like age and immune health [24].
* **Myeloma:** Myeloma, also known as multiple myeloma, affects plasma cells—a type of white blood cell that produces antibodies. Myeloma cells accumulate in the bone marrow and can weaken bones, leading to fractures and other complications. It's a type of cancer that typically affects older adults [25].
	1. **Cancer of neuroectodermal origin**

Cancers of neuroectodermal origin arise from cells that belong to the neuroectoderm, which is a layer of embryonic tissue that gives rise to the nervous system and certain other tissues. These cancers are often referred to as neuroectodermal tumors and can manifest in various parts of the body, including the central nervous system, peripheral nerves, and other tissues derived from the neuroectoderm.

One of the most well-known types of neuroectodermal tumors is neuroblastoma, which primarily affects young children and usually originates in the adrenal glands. Another example is medulloblastoma, a type of brain tumor that mainly affects children. These tumors can also arise in tissues such as the retina (retinoblastoma) or peripheral nerves (peripheral neuroectodermal tumors or PNETs) [26].

**Table 2: Overview of different types of cancer with examples.**

|  |  |  |  |
| --- | --- | --- | --- |
| CATEGORY | TYPES | EXAMPLES | REFERENCES |
| Carcinoma | Squamous Cell CarcinomaAdenocarcinoma | Lungs, breast, colon, prostate, etc. | [16] |
| Sarcoma  | AngiosarcomaOsteosarcomaChondrosarcomaLeiomyosarcomaRhabdomyosarcoma Liposarcoma GliomaMesenchymous sarcoma Fibrosarcoma  | Blood VesselsBonesCartilage Smooth MuscleSkeletal muscle Adipose tissueNeurogenic tissue in brainMixed connective tissueFibrous tissue | [19] |
| Leukemia Lymphoma Myeloma  | Myelogenous or granulocyticPolycythaemia veraLymphatic or lymphoblastic Non – Hodgkin lymphomaHodgkin lymphoma - | Myeloid and GranulocyteBlood cellsLymphoid and lymphocyticBrain, breast or stomach Plasma cells of bone marrow. | [20, 21][22, 23, 24][25] |
| Mixed Types  | Adenosquamous carcinomaMixed mesodermal tumor carcinosarcoma | Lungs, breast, colon, etc. | [27] |

1. **Clonal Evolution of Cancer**
	1. **Monoclonal theory of cancer origin**

The monoclonal theory of cancer origin proposes that, in most cases, neoplasms or tumors arise from a single precursor cell. While certain factors might induce mutations in multiple cells simultaneously, the majority of tumor masses are derived from the descendants of a single cell or a very limited number of cells [28]. This theory underscores the concept that cancer development is a result of accumulated mutations in the genetic material of a single cell, causing it to progress from a normal state to a pre-malignant state, and eventually transforming it into a fully malignant cancer cell [29]. The accumulation of mutations ultimately results in the acquisition of the ten recognized hallmarks of cancer, which include traits like sustained proliferative signaling, evasion of growth suppressors, resistance to cell death, and induction of angiogenesis, among others. As these cells continue to divide and acquire additional mutations, they give rise to the diverse subpopulations of cancer cells that contribute to tumor heterogeneity. The monoclonal theory aligns with the concept of clonal evolution, wherein cancer cells continue to accumulate genetic alterations, leading to the emergence of more aggressive, treatment-resistant, and invasive subclones [30].

* 1. **Cancer stem cells**

The term "cancer stem cell" refers to the initial malignant cell responsible for tumor formation [31, 32]. The cancer stem-cell hypothesis is founded on the recognition of the heterogeneity present in many tumors – the diversity in cell phenotype and function [32]. Research underscores the existence of a cellular hierarchy within tumors, particularly highlighting a small subset comprising approximately 0.2%–1% of cells that exhibit stem cell-like attributes [33]. These cancer stem cells possess distinctive qualities. They can give rise to various cell types within the tumor tissue, maintain self-renewal capabilities indefinitely, and, significantly, can generate new tumors upon transfer. This suggests that cancer stem cells are exclusively capable of initiating tumorigenesis. The hypothesis lends insight into phenomena like metastasis and remission, potentially elucidating their mechanisms.

Both the model that is the monoclonal model of cancer and the cancer stem-cell model are not mutually exclusive [34]. The emergence of a cancer stem cell arises via clonal evolution due to the selective advantage it holds within the neoplasm. Consequently, the tumor's heterogeneous nature can be attributed to two processes – clonal evolution and hierarchical cell differentiation governed by cancer stem cells. While all cancers result from somatic evolution, only a subset align with the cancer stem cell hypothesis.

The evolutionary process doesn't halt once a population of cancer stem cells develops in a tumor. Therapeutic drugs exert potent selective pressures on all tumor cells, including cancer stem cells, compelling them to evolve resistance. It's notable that cancer stem cells needn't always exhibit the highest resistance to therapy within the tumor. Surviving cells might be positioned within a specialized microenvironment that shields them from treatment's adverse effects [35].

A fundamental question remains regarding the origin of cancer stem cells. It's uncertain whether they arise from the transformation of adult stem cells, a halt in progenitor cell maturation, or even the dedifferentiation of mature cells. This ambiguity underscores the ongoing exploration into the complex biology of cancer stem cells and their pivotal role in tumor initiation and treatment resistance [33].

1. **Properties of Cancer**

Cancer cells have several distinct properties that set them apart from normal cells. These properties contribute to the uncontrolled growth and spread of cancer.

**Some key properties of cancer cells are:**

* **Uncontrolled Growth:** Unlike normal cells that follow a regulated pattern of growth and division, cancer cells divide rapidly and uncontrollably. This leads to the formation of tumors [1, 36].
* **Immortality:** Normal cells have a limited number of divisions they can undergo before entering a state of senescence or cell death. Cancer cells, however, can avoid this limit and continue dividing indefinitely, which contributes to tumor growth [37].
* **Angiogenesis:** Cancer cells can stimulate the growth of new blood vessels (angiogenesis) to supply nutrients and oxygen to the growing tumor. This helps the tumor establish a network of blood vessels to sustain its growth [38].
* **Invasion and Metastasis:** Cancer cells can invade surrounding tissues and organs, breaking through barriers that would normally contain normal cells. In some cases, cancer cells can detach from the primary tumor, travel through the bloodstream or lymphatic system, and establish secondary tumors in distant parts of the body (metastasis) [39].
* **Resistance to Apoptosis:** Apoptosis is programmed cell death, a natural process that eliminates damaged or unnecessary cells. Cancer cells often evade apoptosis, allowing them to survive and accumulate despite genetic abnormalities or harmful conditions [40].
* **Altered Cellular Metabolism:** Cancer cells change their metabolism to support their rapid growth. They often favour glycolysis, a process that breaks down glucose for energy even in the presence of oxygen (the Warburg effect), which is different from the energy production of normal cells [41].
* **Genomic Instability:** Cancer cells tend to have genetic mutations and instability. This can lead to a wide range of genetic changes that contribute to tumor development and progression [42, 43].
* **Evading Immune Detection:** Cancer cells can avoid recognition by the immune system, allowing them to grow without being attacked by the body's defense mechanisms. This involves mechanisms that suppress immune responses or hide from immune cells [44].
* **Deregulated Signaling Pathways:** Cancer cells often have altered signaling pathways that control cell growth, division, and other important processes. These alterations contribute to the uncontrolled growth of cancer cells [45].
* **Heterogeneity:** Within a single tumor, there can be a variety of cancer cells with different genetic and molecular characteristics. This heterogeneity can make treatment more challenging, as some cells might be more resistant to therapies than others [46].

These properties collectively enable cancer cells to grow uncontrollably, invade surrounding tissues, and spread to distant sites in the body, ultimately causing the harm associated with cancer.

1. **Causes**

The vast majority of cancer cases, accounting for approximately 90-95% of instances, stem from genetic mutations prompted by environmental and lifestyle factors. The remaining 5-10% can be attributed to hereditary genetic predispositions. Cancer emerges through the transformation of normal cells into tumor cells, following a multi-stage progression from pre-cancerous lesions to full-blown malignant tumors. This complex process is a result of the interplay between an individual's genetic factors and three primary categories of external agents:

1. **Physical Carcinogens:** These agents include ultraviolet and ionizing radiation, both of which can damage cellular DNA and trigger mutations that contribute to cancer development [47, 48].
2. **Chemical Carcinogens:** According to WHO (World Health Organization) Substances like asbestos, components found in tobacco smoke, alcohol, aflatoxin (a contaminant in food), and arsenic (a contaminant in drinking water) fall into this category. They can disrupt cellular processes and instigate genetic mutations that promote cancer progression [47, 48].
3. **Biological Carcinogens:** Infections caused by specific viruses, bacteria, or parasites are classified as biological carcinogens. These pathogens can alter cellular behaviour, disrupt immune responses, and generate chronic inflammation, all of which contribute to the transformation of normal cells into cancerous ones [48].

The International Agency for Research on Cancer (IARC), a branch of the World Health Organization (WHO) dedicated to cancer research, curates a thorough classification of agents recognized for their potential to induce cancer. This categorization significantly contributes to the comprehension of cancer-causing factors and the advancement of preventive endeavours.

As individuals age, the incidence of cancer experiences a sharp increase. This phenomenon can be attributed to the accumulation of risks associated with specific cancers that intensify with age [49]. This cumulative risk is compounded by the diminishing effectiveness of cellular repair mechanisms as the body matures.

In essence, the development of cancer is a complex interplay between genetic factors and exposure to external agents, including physical, chemical, and biological carcinogens. The aging process further exacerbates cancer risk due to the accumulation of mutational and environmental factors, coupled with reduced cellular repair capabilities.

1. **Molecular basis of Cancer**

Cancer is a group of diseases characterized by the self-directed growth of neoplastic cells, showcasing an array of modifications, notably mutations and genetic instability, within their biological makeup. The molecular basis of cancer involves the intricate genetic and molecular changes that occur within cells, leading to the development and progression of cancer. These changes are driven by alterations in the DNA sequence, gene expression, and Signaling pathways that control cell growth, division, and survival [50].

Genes undergoing both genetic and epigenetic alterations, which collectively contribute to the initiation and progression of cancer, are referred to as **cancer critical genes (**or **driver genes** or **cancer-related genes)** [50]**.** These genes may involve in the processes such as cell cycle progression, differentiation, DNA repairing and cell death. These genes harbor mutations or alterations that directly contribute to the transformation of normal cells into cancer cells. Unlike passenger genes, which acquire mutations but don't significantly impact cancer development, driver genes have a direct influence on the cellular processes that underlie cancer formation.

**Cancer critical genes can be grouped into two broad classes based on their functions and roles in cancer development:**

* 1. **Proto – oncogenes**

A proto-oncogene is a gene that is normally present within a cell. Numerous proto-oncogenes exist in the cellular environment [51, 52]. These genes play crucial roles in regulating normal cell growth, division, and differentiation. The proteins encoded by these genes encompass growth factors, growth factor receptors, transcription factors, and signal transducers. Their involvement in the transformation process stems from their ability to propel cell proliferation or diminish sensitivity to cell death. They also play major role in various cellular processes, including growth factor signaling, cell cycle control, DNA repair, and apoptosis (programmed cell death).

A proto-oncogene has the potential to become an oncogene when it undergoes specific mutations or alterations. Various types of genetic and epigenetic alterations can transform proto-oncogenes into oncogenes, driving their abnormal activation and contributing to the development of cancer [53]. These alterations disrupt the normal regulatory mechanisms that control gene expression and cellular processes. Here are some ways in which proto-oncogenes can be converted into oncogenes or the mechanisms associated with proto-oncogene activation include the following [54]:

1. **Point Mutations:** A proto-oncogene has the potential to transform into an oncogene due to a single nucleotide alteration. This alteration could involve base deletion, insertion, or substitution. Irrespective of the mutation type or origin, it typically leads to modifications in the amino acid sequence of the encoded protein, thereby changing its function. A point mutation can either enhance or disrupt gene function. One instance illustrating the transformation from proto-oncogene to oncogene through a point mutation is observed in the RAS proto-oncogenes [54]. In human cells, the HRAS, KRAS, and NRAS genes are closely linked in the RAS gene family [55]. The RAS gene family (HRAS, KRAS, and NRAS) encodes proteins involved in cell signaling pathways that regulate cell growth and division. Mutations in these genes, particularly KRAS, are commonly found in various cancers, such as colorectal cancer and pancreatic cancer [56]. A specific point mutation, such as the KRAS G12D mutation, changes a single DNA base in the gene [57]. This mutation locks the protein in an active state, leading to persistent signaling for cell growth, even in the absence of normal stimuli. As a result, cells with this mutated KRAS gene can undergo uncontrolled proliferation and contribute to tumor formation.
2. **Gene amplification:** Gene amplification refers to the process by which the number of copies of a specific gene within a cell is increased, leading to higher expression levels of the encoded protein. In the context of proto-oncogenes, gene amplification can contribute to the development of cancer by increasing the activity of the encoded proteins involved in promoting cell growth, proliferation, and survival [58].

Proto-oncogenes that are subject to gene amplification can become hyperactive, driving abnormal cellular signaling and uncontrolled division. This process can be a crucial step in oncogenesis, as it can lead to an increased abundance of proteins that stimulate cell growth and inhibit apoptosis. An example of gene amplification in a proto-oncogene is the MYC Gene Amplification. The MYC proto-oncogene encodes a transcription factor that regulates the expression of genes involved in cell growth and proliferation. Amplification of the MYC gene is frequently observed in various cancers, including breast, lung, and ovarian cancers. Increased MYC gene copies lead to elevated levels of the MYC protein, which can drive excessive cell division and contribute to tumorigenesis [58].

1. **Chromosomal Translocations:** Chromosomal translocations are genetic mutations that involve the rearrangement of genetic material between two non-homologous chromosomes. This process occurs when a segment of one chromosome breaks and becomes attached to another chromosome. Chromosomal translocations can lead to changes in gene structure, expression, and function, which can have significant implications for cellular processes and disease, including cancer. Chromosomal translocations can lead to the activation of oncogenic pathways when they result in the fusion of a proto-oncogene with another gene [54]. This fusion event often places the proto-oncogene under the control of a highly active promoter, leading to it’s over expression and altered function. The resulting fusion protein can contribute to uncontrolled cell growth and cancer development.

An example of a chromosomal translocation involving proto-oncogenes is **BCR-ABL1 Fusion Gene in Chronic Myeloid Leukemia (CML)**. The BCR-ABL1 fusion gene in CML results from a translocation between chromosomes 9 and 22. The ABL1 gene on chromosome 9 fuses with the BCR gene on chromosome 22, generating the BCR-ABL1 fusion gene. This fusion gene encodes a constitutively active tyrosine kinase that drives the uncontrolled growth of white blood cells in CML [59].

Another example is of **Burkitt’s lymphoma**. It is driven by a chromosomal translocation that fuses the MYC proto-oncogene on chromosome 8 with immunoglobulin genes, often on chromosome 14. This translocation results in the relocation of the **MYC gene** under the control of strong immunoglobulin enhancers. As a consequence, the MYC gene becomes persistently overexpressed, leading to the excessive production of the MYC protein, a transcription factor that regulates genes related to cell growth, proliferation, and apoptosis. The aberrant expression of MYC disrupts normal cellular processes, fostering uncontrolled cell division and the aggressive growth characteristic of Burkitt lymphoma [60].

1. **Insertional activation:** Insertional activation refers to a genetic event in which the normal regulation of a gene is disrupted by its insertion into a different genomic location, often resulting in altered gene expression. This phenomenon can play a role in cancer development when proto-oncogenes, which are genes that regulate normal cell growth, become abnormally activated due to their insertion near strong regulatory elements, such as enhancers, in the genome. This enhanced expression of proto-oncogenes can lead to uncontrolled cell division and contribute to tumorigenesis. Insertional activation can occur through various mechanisms, such as retroviral integration, transposon activity, or other genomic rearrangements, and understanding its implications is crucial for unravelling the molecular basis of oncogenesis [61]. An example of insertional activation of a proto-oncogene is seen in certain cases of human T-cell Leukemia virus type 1 (HTLV-1)-associated Leukemia. HTLV-1 is a retrovirus that can infect T cells. In some individuals infected with HTLV-1, the virus integrates its genetic material into the host cell's genome. This integration can occasionally occur near strong enhancer elements that regulate gene expression [62].

**Table 3: proto-oncogenes, their functions and the cancer associated with mutation in that gene.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Proto -oncogene | Gene location | Protein function | CancerAssociated | References  |
| ABL1BRAFSRCFESLCK | 9q347q3420q11.2315q26.11p35-p34.3 | **PROTEIN KINASE**Tyrosine kinaseTyrosine kinaseSerine – threonine kinaseTyrosine kinaseLymphocyte Tyrosine kinase | Colorectal and breast cancers, melanomas, ovarian cancers, gastric cancers, blood cancer. | [63, 64, 65, 66] |
| ErbB-1 (EGFR)ErbB-2 (HER2) | 7q11.217q12 | **GROWTH FACTOR RECEPTORS**Receptor of epidermal growth factor (EGF)Receptor tyrosine – protein kinase | Breast cancer, pancreatic cancer, gastrointestinal stromal tumors.  | [67,68] |
| SIS Int -2  | 22q12.3-13.111q13 | **GROWTH FACTOR**Platelet-Derived Growth Factor Beta (PDGFB)Fibroblast growth factor (FGF) | Breast carcinoma, glioblastoma, melanomas, fibrosarcomas. | [69, 70] |
| H-RASK-RASN-RAS | 11p15.512p12.11p13.2 | **G-PROTEIN SIGNAL TRANSDUCERS**GTPaseGTPaseGTPase | Thyroid tumors, adenocarcinomas of colon and pancreas, myeloid leukemia. | [55, 56] |
| JUNc-FOSMYC | 1q24.114q24.38q24.21 | **TRANSCRIPTION FACTOR**Nuclear proteinNuclear proteinNuclear protein | Retinoblastoma, malignant T-cell lymphomas, breast cancer, acute myeloid leukemia. | [71] |

* 1. **Tumor Suppressor genes**

Tumor suppressor genes (also called anti-oncogene) are a class of genes that play a critical role in regulating cell division, DNA damage repair, induction of apoptosis and prevent unregulated cell growth [1, 72].

Tumor suppressor genes are commonly categorized into two main types based on their mechanisms of action and the consequences of their inactivation. These are of two types are:

1. **Gatekeeper Genes** arethose genes that directly control cell proliferation and prevent abnormal growth. These genes serve as key regulators of the cell cycle and apoptosis, and their dysfunction can lead to uncontrolled cell division and tumor formation. Tumor suppressor genes, as mentioned in the previous response, often function as gatekeeper genes. They act as barriers against the development of cancer by inhibiting cell growth and promoting cell death in response to DNA damage or other abnormalities. For instance, the **TP53 (p53) gene** is a classic gatekeeper gene. Mutations in p53 result in its loss of function, which can lead to the accumulation of DNA damage and increased survival of damaged cells, increasing the risk of cancer development [1, 73].
2. **Caretaker genes**, on the other hand, are genes that play a crucial role in maintaining the integrity of the genome. They are involved in processes such as DNA repair, replication, and chromosome stability. Caretaker genes do not directly control cell proliferation like gatekeeper genes, but they contribute to the overall stability of the genome. Mutations in caretaker genes can lead to an increased mutation rate and genomic instability, which can create an environment conducive to the development of cancer [73].

Caretaker genes are particularly important because they help prevent the accumulation of mutations that could affect gatekeeper genes and other critical cellular processes. A malfunctioning caretaker gene can result in an increased likelihood of mutations in other genes, including gatekeeper genes, contributing to the progression of cancer.

Tumor suppressor genes can be broadly categorized into several classes based on their functions and mechanisms of action. These categories help us understand the diverse ways in which these genes contribute to preventing the development and progression of cancer:

1. **Cell Cycle Regulators:** These tumor suppressor genes control the cell cycle and ensure that cells divide only when conditions are appropriate. They prevent cells from entering the cell cycle if DNA damage or other abnormalities are detected. Examples include:
* RB1 (Retinoblastoma gene): Regulates the G1/S checkpoint of the cell cycle.
* CDKN2A (p16INK4a): Inhibits cyclin-dependent kinases, slowing down the cell cycle.
* CDKN1A (p21Cip1): Induces cell cycle arrest in response to DNA damage [74].
1. **Apoptosis Inducers:** These genes promote programmed cell death (apoptosis) in cells that are irreparably damaged or abnormal. They prevent the survival and propagation of cells with genetic defects. Examples include:
* TP53 (p53): Activates apoptosis in response to DNA damage and other stress signals [75].
* BAX: Contributes to the initiation of apoptosis by promoting mitochondrial permeabilization [76].
1. **DNA Repair Genes:** These genes are involved in repairing DNA damage, maintaining genomic stability, and preventing the accumulation of mutations that could lead to cancer. Examples include:
* BRCA1 and BRCA2: Involved in homologous recombination repair of DNA double-strand breaks [77].
* MLH1, MSH2, MSH6, PMS2: Mismatch repair genes that correct errors in DNA replication [78].
1. **Chromatin Regulators:** These genes are responsible for maintaining proper chromatin structure and regulating gene expression. Disruption of these genes can lead to epigenetic changes that contribute to cancer. Examples include:
* ATRX: Involved in chromatin remodelling and regulation of telomeres.
* HDAC1, HDAC2: Histone deacetylases that influence gene expression through chromatin modification [79].
1. **Cell Adhesion and Motility Regulators:** These genes help maintain tissue structure and prevent cells from detaching and spreading uncontrollably (metastasis). Examples include:
* E-cadherin (CDH1): Regulates cell-cell adhesion [80].
* NF2 (Merlin): Links cell adhesion to the cytoskeleton and suppresses cell motility [81].
1. **Signaling Pathway Regulators:** These genes modulate various signaling pathways that control cell growth, survival, and proliferation. Mutations can lead to aberrant pathway activation. Examples include:
* PTEN: Regulates the PI3K-Akt pathway involved in cell survival and growth [82].
* APC: Controls the Wnt Signaling pathway, important for cell proliferation [83].

These categories are not always mutually exclusive, as many tumor suppressor genes have multifaceted roles that can span across several functions. However, understanding these general categories helps elucidate how tumor suppressor genes collectively act as safeguards against cancer development by regulating crucial cellular processes.

There are several well-studied tumor suppressor genes (TSGs) that have been extensively researched due to their significant roles in preventing the development of cancer. They are:

1. **TP53(tumor protein 53):** It often referred to as the **"guardian of the genome,"** is one of the most extensively studied tumor suppressor genes due to its critical role in preventing the development of cancer.

**Key Functions:**

* **Cell Cycle Arrest:** When DNA damage is detected, p53 can halt the cell cycle at the G1/S or G2/M checkpoint [84].
* **DNA Repair:** p53 promotes DNA repair mechanisms, allowing cells to fix damaged DNA and maintain genomic stability [85].
* **Apoptosis (Programmed Cell Death):** If DNA damage is severe and cannot be repaired, p53 can induce apoptosis. This eliminates cells with irreparable damage, preventing their survival and potential transformation into cancer cells [75].

**Inactivation and Cancer:** Mutations in TP53 lead to loss of its tumor suppressor functions. Inactivating mutations can result in uncontrolled cell growth, accumulation of DNA damage, and resistance to apoptosis, promoting tumor development. Mutations in TP53 are found in a wide range of cancers, including lung, breast, colorectal, and ovarian cancers, among others. Some individuals inherit a mutated TP53 gene, leading to **Li-Fraumeni syndrome**, a rare hereditary disorder associated with a high risk of developing multiple types of cancers [86].

In summary, TP53 is a pivotal tumor suppressor gene that safeguards genomic integrity, regulates cell cycle progression, and promotes DNA repair and apoptosis. Its dysfunction through mutations contributes to cancer development by allowing cells with damaged DNA to survive and proliferate.

1. **Retinoblastoma 1 (RB1 gene):** It is another well-studied tumor suppressor gene with a critical role in regulating cell cycle progression and preventing the development of cancer.

**Key Functions:**

* **Cell Cycle Regulation:** In its active form, **pRB (protein Retinoblastoma)** binds to E2F transcription factors, preventing them from promoting the expression of genes required for cell cycle progression [87].
* **G1 Arrest:** By inhibiting E2F activity, pRB helps keep the cell in the G1 phase of the cell cycle, preventing entry into the S phase where DNA replication occurs [88].
* **Differentiation Control:** pRB also plays a role in promoting cellular differentiation, which is crucial for the development of specialized tissues [89].

**Inactivation and Cancer:**

Loss of functional RB1 leads to uncontrolled cell cycle progression, as E2F transcription factors are no longer properly regulated. Mutations or other mechanisms that disrupt pRB's inhibitory activity can contribute to the development of cancer. Retinoblastoma, a rare eye cancer that primarily affects children, is associated with RB1 mutations. It was the first cancer linked to a specific genetic mutation [96].

**Two-Hit Hypothesis:**

* The "two-hit" hypothesis, proposed by Alfred Knudson, explains the hereditary nature of retinoblastoma and other cancers related to RB1.
* According to this hypothesis, individuals inherit one mutated copy of RB1 from a parent (the first hit), and then a somatic mutation occurs in the other copy within a cell (the second hit), leading to loss of pRB's function and promoting cancer development [90].
1. **BRCA1 (BReast - CAncer susceptibility gene 1) and BRCA2 (BReast - CAncer susceptibility gene 2):** BRCA1 and BRCA2 are two highly studied tumor suppressor genes that are associated with an increased risk of breast and ovarian cancers, among other cancer types [91].
2. **BRCA1 (BReast - CAncer susceptibility gene 1):**
* **Function:** BRCA1 is involved in multiple cellular processes, including DNA repair, maintenance of genomic stability, cell cycle regulation, and transcriptional control.
* **DNA Repair:** BRCA1 plays a key role in repairing DNA double-strand breaks through homologous recombination repair, a critical process for maintaining genomic integrity.
* **Cell Cycle Regulation:** BRCA1 helps control cell cycle progression and ensures that cells with DNA damage are repaired before proceeding to the next phase.
* **Transcriptional Regulation:** BRCA1 is involved in regulating the transcription of various genes related to DNA repair and other cellular processes [91, 92].
1. **BRCA2 (BReast - CAncer susceptibility gene 2):**
* **Function:** BRCA2 also plays a crucial role in DNA repair, specifically in homologous recombination repair of DNA double-strand breaks.
* **DNA Repair Facilitator:** BRCA2 helps load RAD51 onto single-stranded DNA, a key step in the homologous recombination process.
* **Genomic Stability:** By assisting in proper DNA repair, BRCA2 helps maintain genomic stability and prevent the accumulation of harmful mutations [91, 92].

**Cancer Risk and Inactivation:**

* Inherited mutations in BRCA1 and BRCA2 significantly increase the risk of developing breast, ovarian, and other cancers, often at a younger age than in the general population [93].
* Women with BRCA1 mutations have a lifetime risk of approximately 50-85% for breast cancer and a 20-40% risk for ovarian cancer [94].

**Hereditary Breast and Ovarian Cancer (HBOC) Syndrome:**

* BRCA1 and BRCA2 mutations are associated with hereditary breast and ovarian cancer syndrome, a condition characterized by an increased risk of these cancers.
* Genetic testing can identify individuals with BRCA1 or BRCA2 mutations, allowing for proactive medical management and risk reduction strategies [93].

**Table: tumor- suppressor genes, their functions and the cancer associated with mutation in that gene.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Tumor suppressor genes | Gene location | Function | Cancer associated | References  |
| TP53 | 17p13.1 | Transcription factor | Lung, colorectal, breast, ovarian, and many others. | [95] |
| RB1 | 13q14 | Cell cycle control | Retinoblastoma (eye cancer), osteosarcoma. | [96] |
| DCC | 18q21.3 | Cell – cell adhesion | Colorectal Cancer | [97] |
| NF1 | 17q11.2 | Growth signal transduction | Neurofibromatosis type 1 (NF1) syndrome, neurofibromas | [98] |
| APC | 5q21 | Cell – matrix adhesion | Colorectal cancer, familial adenomatous polyposis (FAP). | [83] |
| MTS1 | 9p21 | Cell cycle control  | Melanoma, pancreatic cancer, thyroid carcinoma, endometrial cancer. | [99, 100] |
| MSH2 | 2p22 | DNA repair | Lynch syndrome-related cancers, primarily colorectal cancer, endometrial cancer. | [100] |
| VHL | 3p25-26 | Cellular response | renal cell carcinoma, hemangioblastomas | [101] |
| MLH1 | 3p21.3 | DNA repair | Lynch syndrome-related cancers, primarily colorectal cancer, endometrial cancer. | [100, 101] |
| BRCA1 | 17q21 | DNA repair | Breast and ovarian cancers | [101] |
| BRCA2 | 13q12.3 | DNA repair | Breast and ovarian cancers | [101] |
| PTEN | 10q23.3 | Cell cycle regulation | Breast, prostate, and brain cancers | [82] |

1. **Metastasis**

Metastasis entails a multifaceted progression during which cancer cells disperse from the initial tumor location to distant areas within the body. This results in the formation of secondary tumors, also known as metastases. It is a hallmark of malignant cancer and is responsible for the majority of cancer-related deaths.

 **The process of metastasis involves several distinct steps:**

1. **Local Invasion:**
* Cancer cells at the primary tumor site acquire the ability to invade surrounding tissues.
* They break through the basement membrane and invade nearby blood vessels or lymphatic vessels [102].
1. **Intravasation:**
* Cancer cells enter the bloodstream or lymphatic system through blood vessels or lymphatic vessels.
* They can survive in the circulation despite the hostile environment [102, 103].
1. **Circulation:**
* Cancer cells are carried through the bloodstream or lymphatic system to distant organs or tissues.
* Most circulating cancer cells do not survive this journey due to various challenges, including immune responses and physical forces [103].
1. **Arrest and Extravasation:**
* Cancer cells that successfully reach distant organs encounter small blood vessels called capillaries.
* They arrest, or stop, in these capillaries, often in microvasculature of target organs.
* Cancer cells then squeeze out of the vessels and enter the surrounding tissue, a process called extravasation [103].
1. **Formation of Micrometastases:**
* Extravasated cancer cells form small clusters of cells in the new tissue, known as Micrometastases.
* Micrometastases may remain dormant for a period of time before initiating growth [103].
1. **Angiogenesis and Macrometastases:**
* Micrometastases can stimulate angiogenesis, the growth of new blood vessels, to supply nutrients and oxygen for sustained growth.
* This enables the formation of larger secondary tumors called macrometastases [103].

Metastasis is a complex and multifaceted process influenced by various factors, including the cancer type, genetic alterations in the cancer cells, interactions with the tumor microenvironment, and immune responses. The ability of cancer cells to metastasize often determines the severity and stage of cancer, as well as treatment strategies. Understanding the mechanisms of metastasis is crucial for developing targeted therapies that can inhibit or disrupt the various steps involved in the process. Researchers are actively working to identify key molecular pathways and cellular interactions involved in metastasis to develop more effective treatments and interventions that can prevent or limit the spread of cancer to distant sites in the body.

1. **Cancer Microenvironment and Immune Response**

The tumor microenvironment refers to the complex ecosystem of cells, molecules, and structures that surround a tumor within the body. This microenvironment plays a critical role in shaping the behaviour of the tumor, its growth, invasion, and response to therapies. It encompasses various cell types, such as immune cells, fibroblasts, endothelial cells, and tumor cells themselves, along with extracellular matrix components and signaling molecules [104]. The interactions between these components can influence the progression and treatment outcomes of cancer. The tumor microenvironment represents a vibrant field of study and a crucial focal point in devising impactful cancer treatments that consider the ever-changing interactions unfolding within and surrounding the tumor.

**Components of the Tumor Microenvironment:**

1. **Tumor Cells:** It is the central component of the microenvironment. Tumor cells drive the formation and progression of cancer [104, 105].
2. **Stromal Cells:**
* **Fibroblasts:** Cancer-associated fibroblasts (CAFs) are key players in tumor progression. They promote tissue remodelling, angiogenesis, and immune evasion.
* **Endothelial Cells:** Form blood vessels that supply nutrients and oxygen to the tumor (angiogenesis)**.**
* **Immune Cells:** Tumor-infiltrating lymphocytes (TILs), including T cells, B cells, and natural killer cells, have complex interactions with tumor cells [104].
1. **Extracellular Matrix (ECM):** A network of proteins and carbohydrates that provides structural support to tissues. Altered ECM can affect cell behaviour and tumor invasion.
2. **Immune Cells:**
* **T Cells:** Some T cells recognize and attack tumor cells, while others, like regulatory T cells (Tregs), suppress immune responses.
* **Dendritic Cells:** Antigen-presenting cells that initiate immune responses by presenting tumor antigens to T cells.
* **Myeloid-Derived Suppressor Cells (MDSCs):** Suppress immune responses, promoting tumor growth [104, 105].
1. **Cytokines and Chemokines:** Signaling molecules that mediate communication between different cell types in the microenvironment [104].
2. **Blood vessels:** Angiogenesis, the formation of new blood vessels, is critical for delivering nutrients and oxygen to the tumor and facilitating metastasis [104].

**Functions and Dynamics:**

1. **Immune Response and Immunomodulation:**

Tumor cells can evade immune recognition by downregulating major histocompatibility complex (MHC) molecules. Immune checkpoint molecules like PD-1 and CTLA-4 can suppress T cell activity, promoting immune evasion. Some tumors exhibit an "immune desert" microenvironment with few immune cells, while others have an "inflamed" microenvironment with active immune responses [106].

1. **Angiogenesis and Hypoxia:**

Tumors release angiogenic factors that stimulate blood vessel growth, ensuring a blood supply. Rapid tumor growth can outpace blood vessel formation, leading to areas of low oxygen (hypoxia), nutrient deprivation. Hypoxia triggers the production of angiogenic factors, primarily vascular endothelial growth factor (VEGF), which stimulates the sprouting of new blood vessels from nearby existing ones. The newly formed blood vessels supply the tumor with oxygen and nutrients, enabling its continued growth and survival [38].

1. **Matrix Remodelling and Metastasis:**

The ECM influences tumor cell behaviour and invasion. Matrix metalloproteinases (MMPs) produced by tumor and stromal cells degrade the ECM, aiding tumor cell movement and metastasis [107].

1. **Interaction with Therapies:**

The microenvironment can influence how tumors respond to therapies like chemotherapy, radiation, and immunotherapy. Dense ECM can limit drug penetration, while immunosuppressive factors can hinder immunotherapy efficacy [108].

1. **Diagnosis**

The diagnosis of cancer represents a pivotal juncture in the management of this complex disease. Cancer detection initially hinges on evaluating an individual's clinical symptoms, physical examination findings, and occasionally outcomes from screening assessments. In some instances, fortuitously obtained X-rays for unrelated purposes, such as injury evaluations, may reveal anomalies suggesting cancer. Substantiating the presence of cancer necessitates additional evaluations, commonly referred to as diagnostic tests.

Subsequent to a cancer diagnosis, a crucial procedure known as staging ensues. Staging involves categorizing the cancer's progression, encompassing parameters like its dimensions and whether it has disseminated to adjacent tissues, lymph nodes, or more distant organs. This staging process facilitates informed therapeutic decisions and prognostication.

**Various methods of diagnosis are:**

* 1. **Imaging tests**

In the realm of cancer suspicion, medical practitioners frequently initiate the diagnostic journey with a preliminary step: employing various imaging studies to shed light on potential anomalies. These investigative techniques, encompassing X-rays, ultra-sonography, and computed tomography (CT), serve as the initial diagnostic guideposts.

**Types of Imaging Tests:**

* **X-rays:** X-rays use a small amount of radiation to create images of bones and tissues. They can reveal tumors or abnormal growths within the body.
* **Computed Tomography (CT) Scan:** It provides detailed cross-sectional images of the body. They are used to visualize the size, shape, and location of tumors, as well as detect metastases.
* **Magnetic Resonance Imaging (MRI):** MRI uses strong magnets and radio waves to create detailed images of soft tissues. It's especially useful for evaluating brain, spinal, and musculoskeletal tumors [109].
* **Ultrasound:** Ultrasound uses sound waves to create real-time images of internal organs. It's often used to guide biopsies and assess the characteristics of tumors.
	1. **Biopsy**

A biopsy is a definitive diagnostic procedure in which a sample of tissue or cells is removed from a suspicious area and examined under a microscope to determine if cancer is present. Biopsies provide crucial information about the type of cancer, its aggressiveness, and potential treatment options.

**Biopsy Process:**

* A biopsy is often guided by imaging techniques such as ultrasound, CT, or MRI to precisely target the suspicious area.
* The collected tissue is sent to a pathologist, who examines it under a microscope to determine if cancer cells are present.
* The pathologist analyses the tissue's characteristics, including cell type, grade, and molecular markers.
* Various types of Biopsies are needle biopsy, surgical biopsy and endoscopic biopsy.

Biopsies offer a direct evaluation of tissue, enabling accurate diagnosis and guiding treatment decisions. Together, imaging tests and biopsies form a crucial diagnostic duo, providing comprehensive insights into the nature and extent of cancer.

* 1. **Molecular diagnosis**

Molecular diagnosis involves the analysis of genetic and molecular alterations within an individual's cells to understand disease processes, identify genetic mutations, and tailor treatment approaches. This advanced diagnostic approach delves into the molecular and genetic characteristics of diseases, including cancer. Here's what comes under molecular diagnosis:

1. **Genetic testing**
2. **Mutation Analysis:** Identifying specific mutations or alterations in genes associated with diseases, such as cancer-related mutations in BRCA1 and BRCA2 genes for breast cancer.
3. **Genomic Sequencing:** Analysing the entire DNA sequence of a genome to identify genetic variations linked to diseases.
4. **Biomarker Analysis: Tumor markers**

Tumor markers are substances produced by normal cells or cancer cells in the body that can be detected in blood, urine, or other bodily fluids. These substances are often proteins, enzymes, hormones, or other molecules that can provide information about the presence, characteristics, and behaviour of cancer [110]. Tumor markers are used as diagnostic tools to aid in the detection and management of cancer, as well as to monitor treatment responses and predict prognosis. Elevated levels of specific tumor markers may indicate the possibility of cancer, but they are not definitive proof of the disease and need to be interpreted in conjunction with other clinical and diagnostic information. Different types of cancer may be associated with different tumor markers, making them valuable tools in tailoring treatment approaches and guiding patient care.

Sometimes, these markers aren't in the blood but are on the surface of the tumor cells. To find these, doctors examine a tiny piece of tissue taken during a biopsy. Examples of these markers are HER2 and EGFR, and they help doctors understand the characteristics of the cancer cells.

Some examples of tumor marker are as follows:

1. **Prostate-Specific Antigen (PSA)**
* **Associated with:** Prostate cancer.
* **Role:** Elevated levels can suggest prostate cancer or other prostate conditions.
* **Clinical Use:** Used for prostate cancer screening and monitoring treatment effectiveness [111].
1. **Carcinoembryonic Antigen (CEA)**
* **Associated with:** Various cancers, including colorectal, pancreatic, and lung cancers.
* **Role:** Elevated levels can indicate the presence of certain cancers.
* **Clinical Use:** Used in monitoring treatment response and detecting cancer recurrence [112].
1. **HER2 (Human Epidermal Growth Factor Receptor-2)**
* **Associated with:** Breast and stomach cancers.
* **Role:** Over-expression indicates aggressive cancer and helps guide treatment decisions.
* **Clinical Use:** Used to guide targeted therapies in HER2-positive breast and stomach cancers [113].
1. **Next Generation Sequencing**

Next-Generation Sequencing (NGS) has revolutionized the study of cancer genomics by enabling comprehensive analyses of tumor DNA and RNA. This cutting-edge technology has unravelled the intricate genetic alterations driving cancer development, offering unprecedented insights into tumor biology, personalized treatment strategies, and the potential for targeted therapies [114].

* NGS allows for the simultaneous sequencing of thousands of genes, revealing mutations, copy number variations, and structural alterations that contribute to cancer initiation and progression. NGS helps distinguish driver mutations (contributing to cancer growth) from passenger mutations (non-functional alterations), aiding in identifying potential therapeutic targets. It unveils the heterogeneity within tumors, showing how different regions of a tumor can harbour distinct genetic alterations. This information informs treatment decisions and predicts treatment resistance.
1. **Polymerase Chain Reaction (PCR)**

Polymerase Chain Reaction (PCR) is a genetic powerhouse driving cancer research. By rapidly copying and amplifying specific DNA sequences, PCR empowers scientists to identify cancer-related mutations, markers, and expression patterns. This technique plays a vital role in diagnosing genetic mutations linked to cancers, assessing treatment responses, and tracking minimal residual disease. PCR variants like quantitative PCR (qPCR) and reverse transcription PCR (RT-PCR) expand its capabilities, allowing precise quantification of gene expression and analysis of RNA-based markers. As cancer care evolves, PCR remains an indispensable tool for deciphering the genetic intricacies of tumors, advancing precision medicine, and ultimately improving patient outcomes [115].

1. **Fluorescence In-Situ Hybridization (FISH)**

It is a game-changing technique reshaping cancer diagnostics. By applying fluorescent probes that specifically bind to target DNA sequences within cells, FISH brings genetic information into vivid view. This approach enables the detection of genetic anomalies, structural changes, and gene amplifications associated with cancer. FISH is pivotal in cancer subtyping, aiding in precise classification, prognosis prediction, and treatment planning. Notably, FISH's role in determining the HER2 status in breast cancer guides the selection of targeted therapies. Despite its challenges in interpretation and sample handling, FISH's potential remains vast, offering insights into treatment responses, monitoring minimal residual disease, and driving further advances in understanding cancer genetics. As technology advances, FISH's impact is set to expand. Its ability to identify fusion genes and provide insights into mechanisms of treatment resistance holds promise for the development of more effective therapies [116].

1. **Microarray Analysis**

Microarray analysis is a cutting-edge genomic technology that has revolutionized cancer research by enabling the simultaneous study of thousands of genes' activities. This technique offers a panoramic view of gene expression patterns, mutations, and alterations within cancer cells, shedding light on the intricate molecular landscape of tumors. Microarrays consist of tiny spots containing DNA probes that correspond to specific genes. When fluorescently labelled samples are applied to the microarray, they bind to their complementary DNA probes, producing a colourful pattern that reflects gene expression levels. This approach facilitates the identification of genes that are overexpressed or suppressed in cancer, aiding in cancer subtyping, prognosis prediction, and even the discovery of potential therapeutic targets [117].

Microarray analysis plays a pivotal role in deciphering the genetic underpinnings of cancer. It aids in classifying tumors based on distinct expression profiles, which can guide treatment decisions. Microarrays also contribute to identifying molecular signatures associated with drug responses, allowing tailored therapies. Moreover, this technology delves into the complexity of cancer progression by uncovering genes involved in metastasis, angiogenesis, and immune response. Despite challenges in data analysis and interpretation, microarray analysis stands as a beacon guiding us through the labyrinthine pathways of cancer genetics, offering valuable insights into the mechanisms driving this complex disease.

1. **Circulating Tumor DNA (ctDNA)**

Circulating Tumor DNA (ctDNA) analysis is a groundbreaking method reshaping cancer diagnostics and monitoring. As tumors shed fragments of their DNA into the bloodstream, ctDNA provides a non-invasive liquid biopsy, capturing a snapshot of the tumor's genetic landscape. This approach enables the detection of genetic alterations that drive cancer growth, allowing oncologists to track treatment responses, detect disease recurrence, and guide personalized therapeutic strategies. ctDNA's significance lies in its potential for early cancer detection, as well as its ability to monitor minimal residual disease after treatment, which is pivotal for timely interventions.

ctDNA analysis revolutionizes cancer care by offering real-time genetic insights without the need for invasive procedures. However, challenges encompass ensuring the sensitivity and specificity of ctDNA detection methods, as well as standardizing interpretation across laboratories. As technology advances and methods mature, ctDNA analysis holds immense promise for transforming the landscape of cancer diagnosis, treatment, and monitoring [118].

1. **Therapeutic Approaches and Treatment**

Cancer treatment refers to the various methods and strategies used to manage, cure, or control the growth of cancer cells in the body. The approach to cancer treatment depends on the type and stage of cancer, as well as the patient's overall health and preferences. Cancer treatment can involve one or a combination of the following methods:

* 1. **Surgery**

Surgery involves physically removing the cancerous tumor and, in some cases, nearby lymph nodes or other affected tissues. It is often used for localized tumors that have not spread to other parts of the body.

**13.2 Chemotherapy**

Chemotherapy encompasses the utilization of medications to eliminate or impede the proliferation of cancer cells. These drugs can be administered orally or intravenously and circulate throughout the body to target cancer cells. Chemotherapy is often used when cancer has spread or has a high risk of spreading. Chemotherapy is a cancer treatment that uses powerful drugs to target and destroy rapidly dividing cells, including cancer cells. It's one of the most common treatment options for various types of cancer. Chemotherapy drugs can be administered through different methods, such as intravenous (IV) infusion, oral pills, injections, or even directly into a specific area of the body.

Here's how chemotherapy works:

* **Targeting Rapidly Dividing Cells:** Cancer cells divide and grow at a faster rate than most normal cells. Chemotherapy takes advantage of this characteristic by attacking cells that are actively dividing. While cancer cells are the primary target, other rapidly dividing cells in the body can also be affected. This is why chemotherapy can lead to side effects, as normal cells like hair follicles, bone marrow cells, and cells lining the digestive tract are impacted [119].
* **Disrupting Cell Division:** Chemotherapy drugs work by interfering with various stages of the cell cycle, which is the process that cells go through to divide and grow. Different chemotherapy drugs target different parts of the cell cycle. For example, some drugs prevent DNA replication, which is necessary for cell division, while others inhibit cell division itself.
* **Killing Cancer Cells:** Chemotherapy drugs cause damage to the DNA inside cancer cells. When the cancer cells attempt to divide, the damaged DNA prevents proper cell division. This ultimately leads to the destruction of the malignant cells. However, not all cancer cells may be destroyed in a single treatment cycle, which is why chemotherapy is often given in cycles with rest periods in between.
* **Combination Therapy:** Sometimes, multiple chemotherapy drugs are used together in what's known as combination therapy. Each drug may target different aspects of the cancer cells' growth process, making the treatment more effective. Combination therapy can also reduce the risk of cancer cells developing resistance to a single drug [120].
* **Specific Schedules:** Chemotherapy is often administered in **cycles**. A cycle typically consists of a treatment phase followed by a rest period. This helps to give the body time to recover from the effects of the chemotherapy while allowing the cancer cells to be targeted during subsequent treatment sessions.

**Few examples of chemotherapy drugs along with the types of cancers they are commonly used to treat:**

* **Doxorubicin (Adriamycin):** This drug is used to treat a variety of cancers, including breast cancer, lung cancer, and Leukemia. It works by damaging DNA within cancer cells, which interferes with their ability to divide and grow [121].
* **Cisplatin:** It is often used to treat testicular, ovarian, bladder, and lung cancers. It works by forming crosslinks in DNA, preventing the DNA from being replicated and leading to cell death [122].
* **Paclitaxel (Taxol):** Paclitaxel is used to treat breast, ovarian, and lung cancers. It interferes with the normal breakdown of microtubules during cell division, disrupting the process and causing cell death [123].
* **Fluorouracil (5-FU):** This drug is commonly used for colorectal, breast, and pancreatic cancers. It interferes with the synthesis of DNA and RNA, preventing cell division and leading to cell death [124].
* **Methotrexate:** It is used to treat various cancers, including leukemia, lymphoma, and breast cancer. It interferes with the metabolism of folic acid, which is necessary for DNA synthesis and cell division [125].
* **Trastuzumab (Herceptin):** Trastuzumab is used to treat HER2-positive breast cancer. It targets a specific protein on the surface of cancer cells, inhibiting their growth [126].
	1. **Radiation therapy**

Radiation therapy, also known as radiotherapy, is a common treatment for cancer that uses high doses of radiation to target and destroy cancer cells while minimizing damage to nearby healthy tissues. It is often used alongside surgery, chemotherapy, or other treatments to effectively manage or cure cancer. Radiation therapy works by damaging the DNA within cells, preventing them from dividing and growing.

**Types of Radiation:** There are two primary types of radiation therapy: external beam radiation and internal radiation (brachytherapy).

* **External Beam Radiation:** This is the most predominant form of radiation therapy. It entails administering radiation externally through a device known as a linear accelerator. The machine focuses radiation beams precisely on the tumor site while minimizing exposure to healthy tissues.
* **Brachytherapy:** In this approach, radioactive sources are placed directly inside or very close to the tumor. This allows for a high dose of radiation to be delivered directly to the cancer cells while sparing surrounding healthy tissue [127].
	1. **Immunotherapy**

Immunotherapy constitutes a category of cancer treatment that leverages the body's innate immune system to identify, focus on, and eliminate cancer cells. The immune system is a complex network of cells, tissues, and molecules that work together to defend the body against infections and abnormal cells, including cancer cells. Immunotherapy aims to enhance the immune response against cancer by either boosting its activity or removing barriers that prevent the immune system from recognizing and attacking cancer cells effectively.

The immune system operates as a vigilant guardian, inherently equipped to identify and eliminate aberrant cells, thereby pre-emptively inhibiting or retarding the advancement of numerous cancers. Notably, immune cells are frequently detected in the vicinity of tumors, an indication of the immune system's proactive engagement. These immune cells, referred to as tumor-infiltrating lymphocytes (TILs), symbolize the immune system's recognition of the tumor's presence and its commitment to counter it. Significantly, individuals with TILs within their tumors often exhibit more favourable outcomes compared to those whose tumors lack this orchestrated immune response.

While the immune system possesses the capacity to hinder or decelerate cancer progression, cancer cells have evolved strategies to evade annihilation by the immune system. For instance, cancer cells may employ the following tactics:

* **Genetic Modifications:** Cancer cells can undergo genetic mutations that render them inconspicuous to the immune system. These changes obscure their recognition, enabling them to elude the immune response.
* **Inhibitory Surface Proteins:** Some cancer cells showcase surface proteins that effectively deactivate immune cells, orchestrating an impediment to the immune system's vigilant activity. These proteins function as a kind of "off switch" for immune response.
* **Manipulation of Surroundings:** Cancer cells can manipulate neighbouring healthy cells, orchestrating an environment that hampers the immune system's ability to mount an effective response against the cancerous cells [128].

Immunotherapy, a formidable ally in the fight against cancer, seeks to fortify the immune system's efficacy. It achieves this by:

* **Enhancing Recognition:** Immunotherapy bolsters the immune system's capacity to identify cancer cells by pinpointing distinct molecules or antigens on their surfaces. This empowers the immune system to discern between healthy and malignant cells more accurately.
* **Neutralizing Inhibitory Proteins:** Certain immunotherapies, exemplified by checkpoint inhibitors, neutralize the very proteins that cancer cells exploit to suppress immune response. By doing so, they release the "brakes" on the immune system, allowing it to unleash a more robust assault on cancer cells.
* **Stimulating Immune Vigilance:** Immunotherapy amplifies the activity of immune cells like T cells and natural killer cells, the body's defense against cancer cells. This augmented immune response translates to a more effective suppression of cancer growth.
* **Creating a Favourable Context:** Specific immunotherapy approaches reshape the tumor microenvironment, fostering an atmosphere that encourages immune cells to assail cancer cells. This involves orchestrating a shift in the composition of immune cells within the tumor [129].

Through strategic leverage of the immune system's inherent prowess and countering cancer's evasive manoeuvres, immunotherapy emerges as a groundbreaking modality in cancer treatment. It holds the potential not only to invigorate the body's natural defenses against cancer but also to instigate enduring responses and improved prognoses across diverse cancer types.

Various types of immunotherapies are:

1. **Checkpoint Inhibitors:** These drugs block certain proteins on the surface of immune cells or cancer cells, such as PD-1 (programmed cell death protein 1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4). By blocking these proteins, checkpoint inhibitors help prevent cancer cells from evading the immune system's detection, allowing immune cells to attack and destroy the cancer cells more effectively [130].
2. **CAR-T Cell Therapy:** CAR-T cell therapy, short for Chimeric Antigen Receptor T cell therapy, is a revolutionary form of immunotherapy designed to treat certain types of cancer. This innovative approach harnesses a patient's own immune cells to target and destroy cancer cells with remarkable precision. CAR-T cell therapy has shown remarkable success in treating certain blood cancers, particularly leukemia and lymphoma, where other treatments may not be as effective [131].

**How CAR-T cell therapy works?**

* **Collecting T Cells:** The process begins by collecting a patient's T cells, a type of white blood cell crucial for immune response, through a process called leukapheresis. These T cells are then isolated from the rest of the blood.
* **Genetic Engineering:** In the laboratory, the isolated T cells are genetically modified to express chimeric antigen receptors (CARs) on their surface. CARs are synthetic receptors designed to recognize specific antigens found on the surface of cancer cells.
* **Recognition of Cancer Cells:** The engineered CAR-T cells are now capable of recognizing and binding to the targeted antigen on cancer cells, much like a key fitting into a lock. This antigen specificity is crucial for the therapy's accuracy in distinguishing cancer cells from healthy cells.
* **Cell Expansion:** The modified CAR-T cells are cultured and allowed to multiply in large numbers. This process takes a few weeks, resulting in a significant population of CAR-T cells that carry the cancer-targeting receptor.
* **Infusion:** Once a sufficient quantity of CAR-T cells has been generated, they are infused back into the patient's bloodstream. This infusion is a one-time treatment and is often referred to as the "CAR-T cell infusion."
* **Attack on Cancer Cells:** The infused CAR-T cells circulate throughout the body and seek out cancer cells that express the target antigen. Once the CAR-T cells encounter cancer cells, they bind to the antigen and initiate a powerful immune response, leading to the destruction of the cancer cells.
* **Cytokine Release Syndrome (CRS) Management:** CAR-T cell therapy can trigger an immune response that results in the release of cytokines, causing flu-like symptoms and, in severe cases, a condition called cytokine release syndrome (CRS).
* **Long-Term Monitoring:** After the CAR-T cell infusion, patients are monitored closely to assess the therapy's effectiveness and to manage any potential side effects. Follow-up visits and medical evaluations help ensure the ongoing success of the treatment [132].

CAR-T cell therapy has shown remarkable success in inducing remission and even cure in some patients with previously untreatable blood cancers. However, it's important to note that CAR-T cell therapy is complex and requires careful patient selection, monitoring, and management of potential side effects. Research is ongoing to expand the application of CAR-T cell therapy to other types of cancer and to refine the treatment process for broader use.

1. **CAR-M and CAR-NK Therapy:** CAR-M (Chimeric Antigen Receptor- Macrophages) cell therapy and CAR-NK (Chimeric Antigen Receptor- Natural killer) cell therapy, is a newly discovered immunotherapy and various researches are ongoing on this therapy. CAR-T has shown efficacy in haematological cancers, its effectiveness for solid tumors is more challenging due to limited tumor infiltration and an immunosuppressive tumor environment. To this CAR-M and CAR-NK have been introduced as alternative for CAR-T [133].

Both CAR-NK and CAR-M therapies offer intriguing advantages over traditional CAR-T therapy:

* **Limited Toxicity:** CAR-NK cells and CAR-M cells are being explored for their potential to have limited toxicity compared to CAR-T cells, which can cause severe cytokine release syndrome and neurotoxicity in some patients [134].
* **Large-Scale Production:** Generating CAR-NK cells in large quantities appears to be more feasible compared to CAR-T cells, which could lead to broader availability for patients.
* **Phagocytosis and Antigen Presentation:** CAR-M cells, with their phagocytic activity and antigen-presenting capabilities, hold promise for triggering a multifaceted immune response against cancer cells [134].

These alternative approaches signify the dynamic nature of cancer immunotherapy research. While there's still much to explore and understand about CAR-M and CAR-NK therapies, their potential to address the limitations of CAR-T therapy in treating solid tumors is encouraging. As research progresses and clinical trials continue, we may gain more insights into the effectiveness and safety of these therapies, ultimately expanding the toolkit of treatments available to patients with various types of cancers.

* 1. **Targeted Therapy**

Targeted therapy, also known as molecularly targeted therapy, is a type of cancer treatment that specifically targets certain molecules or pathways that are involved in the growth and spread of cancer cells. Unlike traditional chemotherapy, which aims to kill rapidly dividing cells (both cancerous and healthy), targeted therapy is designed to selectively inhibit the growth and survival of cancer cells while minimizing harm to normal cells. This approach takes advantage of the unique characteristics of cancer cells to achieve more precise and effective treatment [135].

**How targeted therapy works?**

* **Identifying Targets:** Before starting targeted therapy, specific molecular targets that are present in the cancer cells need to be identified. These targets can include mutated genes, overexpressed proteins, or other molecules that contribute to cancer growth.
* **Matching Patients to Treatment:** Patients undergo genetic testing or molecular profiling to determine if they have the specific target that the targeted therapy is designed to address. Targeted therapies are often used in cases where the presence of the target is confirmed.
* **Drug Selection:** Once the target is identified, a targeted therapy drug is selected. These drugs are designed to interact with the specific target, disrupting the molecular pathways that are crucial for cancer cell growth.
* **Mechanism of Action:** Different targeted therapies work in various ways. Some inhibit the activity of specific proteins that are driving cancer growth, while others may prevent angiogenesis (formation of new blood vessels to supply the tumor) or disrupt other key processes that promote tumor survival and progression.
* **Personalized Treatment:** Targeted therapy is often considered a form of personalized medicine because it focuses on the individual characteristics of the patient's cancer. The choice of targeted therapy can be influenced by factors such as the specific genetic mutations present in the tumor and the patient's overall health.
* **Combination with Other Treatments:** Targeted therapy can be used alone or in combination with other treatment modalities such as chemotherapy, radiation therapy, or immunotherapy, depending on the type of cancer and the treatment plan.
* **Monitoring and Adjustments:** Patients undergoing targeted therapy are closely monitored for responses to treatment. If the cancer cells develop resistance or the treatment loses effectiveness over time, adjustments to the treatment plan may be made.

Targeted therapy has shown success in treating various types of cancer, including breast cancer, lung cancer, melanoma, and certain types of leukemia. However, like any treatment, it has potential side effects, and its efficacy can vary among individuals based on their specific molecular characteristics. Advances in understanding cancer biology and genetics continue to drive the development of new targeted therapies, offering more precise and tailored options for cancer treatment.

* 1. **Hormone Therapy**

It also known as **endocrine therapy**, is a type of cancer treatment that targets hormones or hormone receptors in order to slow down or inhibit the growth of hormone-sensitive cancers. Many cancers, such as breast cancer and prostate cancer, rely on hormones like estrogen, progesterone, or testosterone to fuel their growth. Hormone therapy disrupts this process by blocking the effects of hormones or reducing their production [136].

**How hormone therapy works?**

* **Hormone-Sensitive Cancers:** Some cancers have receptors on their cells that bind to specific hormones. These cancers are referred to as hormone-sensitive or hormone-receptor-positive cancers. Examples include estrogen receptor-positive (ER-positive) breast cancer and androgen receptor-positive prostate cancer.
* **Blocking Hormone Receptors:** Hormone therapy involves using drugs that either block hormone receptors on cancer cells or interfere with hormone production. For example, in breast cancer, drugs like tamoxifen or aromatase inhibitors are used to block the effects of estrogen on cancer cells.
* **Reducing Hormone Levels:** In some cases, hormone therapy aims to reduce the levels of hormones in the body. This can be done by surgically removing hormone-producing organs (such as ovaries or testicles) or by using medications to suppress hormone production. For instance, in prostate cancer, drugs like LHRH agonists lower testosterone levels.
* **Combination Therapy:** Hormone therapy can be used alone or in combination with other treatments, such as surgery, chemotherapy, or radiation therapy, depending on the cancer's stage and characteristics.

Hormone therapy is particularly effective for hormone-sensitive cancers and can help slow down the progression of the disease, shrink tumors, and improve outcomes. However, its success can vary depending on factors like the type of cancer, the stage of the disease, and the individual patient's response. As with any cancer treatment, the decision to undergo hormone therapy is made based on thorough assessment and discussion with a medical oncologist.

* 1. **Precision medicine**

It is also known as **personalized medicine**, is an innovative approach to medical treatment and healthcare that takes into account individual differences in patients' genes, environments, and lifestyles. The goal of precision medicine is to tailor medical care and treatments to the unique characteristics of each patient, with the aim of improving treatment outcomes, reducing side effects, and enhancing overall patient care [136].

* 1. **Stem Cell Transplant**

A stem cell transplant, also known as a bone marrow transplant or hematopoietic stem cell transplant, is a medical procedure that involves replacing damaged or diseased bone marrow or blood-forming stem cells with healthy ones. This procedure is used to treat various conditions, including certain types of cancers, blood disorders, and immune system disorders [137].

**How it works?**

* **Collection of Stem Cells:** Healthy stem cells can be collected from different sources, including the patient (autologous transplant), a matched donor (allogeneic transplant), or a partially matched donor (haploidentical transplant). The stem cells can be obtained from bone marrow, peripheral blood, or umbilical cord blood.
* **Conditioning:** Before the transplant, the patient typically undergoes a preparatory regimen known as conditioning. This might encompass chemotherapy, radiation therapy, or a hybrid approach involving both modalities. The goal of conditioning is to suppress the recipient's immune system, eradicate cancer cells, and create space in the bone marrow for the new stem cells.
* **Transplant:** The collected healthy stem cells are infused into the patient's bloodstream, similar to a blood transfusion. The stem cells travel to the bone marrow, where they begin to establish new blood cell production.
* **Engraftment:** The transplanted stem cells gradually settle into the bone marrow and start producing new blood cells—red blood cells, white blood cells, and platelets. This process is known as engraftment.
* **Recovery:** During the recovery period, the patient is closely monitored for signs of engraftment, immune system recovery, and potential complications. Supportive care, such as blood transfusions and antibiotics, may be provided as needed [137, 138].

**Stem cell transplants are commonly used to treat:**

* **Leukemia:** Stem cell transplants are used to treat various forms of leukemia, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL) [137].
* **Lymphoma:** Certain types of lymphomas, such as Hodgkin lymphoma and non-Hodgkin lymphoma, can be treated with stem cell transplants, especially when other treatments have not been successful.
* **Multiple Myeloma:** This is a cancer that affects plasma cells in the bone marrow. Stem cell transplants can be used as part of the treatment plan for multiple myeloma patients.
* **Myelodysplastic Syndromes (MDS):** MDS are a group of disorders characterized by abnormal blood cell production. Stem cell transplants can be considered for patients with high-risk MDS.
* **Neuroblastoma:** In some cases of high-risk neuroblastoma, stem cell transplants can be used as part of the treatment strategy.
* **Germ Cell Tumors:** Certain types of germ cell tumors, which arise from the cells that develop into sperm or eggs, can be treated with stem cell transplants in cases of disease relapse [137].
	1. **CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated protein 9)**

It is a revolutionary gene editing technology that has the potential to transform various fields, including cancer treatment. CRISPR-Cas9 allows scientists to precisely modify and edit genes, which opens up new avenues for understanding the genetic basis of cancer, developing targeted therapies, and even potentially modifying cancer cells to make them more susceptible to treatments.

Here are some ways CRISPR-Cas9 is being explored in cancer treatment:

* **Gene Knockout and Functional Studies:** Researchers are using CRISPR-Cas9 to deactivate or "knock out" specific genes in cancer cells to better understand their role in cancer development and progression. By studying the effects of these gene modifications, scientists can identify potential targets for therapies [139].
* **Drug Resistance Reversal:** CRISPR-Cas9 can be used to identify genes that contribute to drug resistance in cancer cells. By inactivating these genes, researchers aim to reverse drug resistance and make cancer cells more sensitive to treatments.
* **Immune System Enhancement:** CRISPR-Cas9 can be used to modify immune cells, such as T cells, to enhance their ability to recognize and attack cancer cells. This approach is being explored in the development of CAR-T cell therapies, where T cells are engineered to express chimeric antigen receptors that target cancer-specific antigens [139].
* **Tumor Suppressor Activation:** Some cancers result from the loss of function of tumor suppressor genes that normally help prevent the development of cancer. CRISPR-Cas9 can potentially restore the function of these genes, inhibiting cancer growth [139].

While the potential of CRISPR-Cas9 in cancer treatment is promising, it's important to note that there are challenges and ethical considerations associated with its clinical application. Ensuring accurate and specific gene editing, minimizing off-target effects, and addressing potential unintended consequences are areas of active research. CRISPR-Cas9 technology is a rapidly evolving field, and ongoing research is exploring its application in cancer treatment.

* 1. **Nanotechnology in Cancer**

It is a cutting-edge field that involves the manipulation of matter at the nanoscale, typically at dimensions less than 100 nanometres. In cancer therapy, nanotechnology offers innovative approaches to diagnose, treat, and monitor cancer. **Nanoparticles**, which are tiny particles with unique properties at the nanoscale, can be engineered to target cancer cells specifically and deliver therapeutic agents with high precision.

**Some ways nanotechnology is being used in cancer therapy:**

* **Targeted Drug Delivery:** Nanoparticles can be loaded with chemotherapy drugs, targeted therapies, or even genes. These nanoparticles can be designed to specifically target cancer cells while minimizing damage to healthy cells. This targeted drug delivery enhances the effectiveness of treatments and reduces side effects [140].
* **Enhanced Permeability and Retention (EPR) Effect:** Nanoparticles can take advantage of the EPR effect, which is a phenomenon that allows them to accumulate preferentially in tumor tissues due to the leaky blood vessels and impaired lymphatic drainage commonly found in tumors. This results in elevated drug concentrations at the tumor site.
* **Photothermal Therapy (PTT):** Some nanoparticles, such as gold nanoparticles, can absorb light and convert it into heat. By accumulating these nanoparticles in tumors and then irradiating them with light, the heat generated can selectively destroy cancer cells while sparing healthy tissue.
* **Hyperthermia:** Nanoparticles can be used to raise the temperature of tumor tissue slightly, which can enhance the effectiveness of radiation therapy and certain chemotherapy drugs.
* **Gene Silencing and Editing:** Nanoparticles can deliver genetic material, such as small interfering RNA (siRNA) or CRISPR-Cas9 components, to inhibit the expression of specific genes or edit them. This approach is particularly useful for targeting genes that drive cancer growth [141].
* **Imaging and Diagnosis:** Nanoparticles can be equipped with contrast agents that improve the visibility of tumors in imaging techniques like magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET). This contributes in early detection and accurate diagnosis.
* **Theranostics:** Some nanoparticles are designed for both therapy and diagnosis. They can carry therapeutic agents and imaging agents simultaneously, allowing for real-time monitoring of treatment effectiveness [142].
* **Immunotherapy Enhancement:** Nanoparticles can be engineered to enhance the delivery of immune checkpoint inhibitors and other immunotherapies to the tumor microenvironment, bolstering the immune response against cancer cells [142].
* **Personalized Medicine:** Nanoparticles can be tailored to individual patients' genetic and molecular profiles, optimizing treatment effectiveness.

**Some specific examples of how nanotechnology is being used in cancer therapy:**

* **Doxil (Liposomal Doxorubicin):** Liposomal doxorubicin is a nanoparticle-based drug delivery system. Doxorubicin, a chemotherapy drug, is encapsulated within liposomes (tiny lipid-based vesicles). Liposomal doxorubicin, marketed as Doxil, is used to treat various types of cancer, including ovarian cancer, multiple myeloma, and Kaposi's sarcoma. The liposomes protect the drug from being broken down too quickly in the body and improve its accumulation at the tumor site, reducing side effects on healthy tissues [143].
* **Abraxane (Nanoparticle Albumin-Bound Paclitaxel):** Abraxane is another nanoparticle-based chemotherapy drug. Paclitaxel, a common chemotherapy agent, is bound to albumin nanoparticles. This formulation improves the solubility of paclitaxel and enhances its delivery to tumors. Abraxane is used to treat breast cancer, pancreatic cancer, and lung cancer [144].
* **Nanoparticle-Loaded Immune Checkpoint Inhibitors:** Nanoparticles can encapsulate immune checkpoint inhibitors, enhancing their delivery to the tumor microenvironment. This can improve the effectiveness of immunotherapy by blocking immune checkpoint proteins that suppress the immune response [145].
	1. **Histotripsy**

Histotripsy is an emerging non-invasive therapeutic technique that uses high-intensity focused ultrasound (HIFU) to precisely target and destroy tissue at the cellular level. While histotripsy is not commonly used as a primary treatment for cancer, it is being investigated for its potential application in cancer treatment and therapy in certain scenarios [146].

It's important to note that while histotripsy holds promise, its clinical use in cancer treatment is still in the experimental and research stages. Challenges include ensuring precise targeting, monitoring treatment effects, and assessing the long-term outcomes of histotripsy for cancer therapy. Clinical trials are being conducted to evaluate the safety, efficacy, and potential benefits of using histotripsy for cancer treatment**.**

1. **Conclusion**

In conclusion, this book chapter has taken a comprehensive journey through the intricate landscape of cancer, encompassing its origins, mechanisms, and the transformative advancements that have reshaped its diagnosis and treatment paradigms. The multifaceted nature of cancer arises from a combination of genetic mutations, environmental influences, and its ability to evade immune surveillance, resulting in uncontrolled proliferation and metastasis. Importantly, the chapter underscores the critical role of early detection facilitated by advanced imaging techniques, biomarker identification, and genetic profiling, all of which contribute to improved treatment outcomes. The evolution of therapeutic approaches from conventional methods to precision-targeted interventions reflects a fundamental shift in the way we combat the disease. Immunotherapy's ability to harness the body's immune response and the revolutionary potential of gene editing techniques exemplify the cutting-edge progress being made. Moreover, the concept of personalized medicine emerges as a central theme, tailoring treatments to individual genetic profiles, optimizing efficacy while mitigating adverse effects.

However, the chapter also acknowledges the challenges that persist, including treatment resistance, the intricate heterogeneity of cancers, and the imperative of ensuring equitable access to advanced therapies across diverse populations. The global pursuit of innovative research, intercontinental collaboration, and the development of novel technologies stand as crucial strategies to overcome these obstacles. Empowering individuals through education about risk factors, preventive strategies, and early symptom recognition serves as a cornerstone in the battle against cancer, equipping individuals with the knowledge needed to take proactive steps toward their own well-being.

Amid the scientific insights and advancements, the chapter celebrates the unwavering hope and resilience demonstrated by cancer survivors, the groundbreaking strides in research, and the unwavering dedication of healthcare professionals worldwide. Ultimately, this collaborative endeavour envisions a future where the impact of cancer is progressively reduced through the fusion of scientific prowess, compassionate care, and a united global effort, transforming the narrative from one of fear into a narrative of hope, triumph, and advancement.

1. **References**
2. Cooper GM. The Cell: A Molecular Approach. 2nd edition. Sunderland (MA): Sinauer Associates; 2000. The Development and Causes of Cancer.
3. Valastyan, S., & Weinberg, R. A. (2011). Tumor metastasis: molecular insights and evolving paradigms. Cell, 147(2), 275-292.
4. Martin, T. A., Ye, L., Sanders, A. J., Lane, J., & Jiang, W. G. (2013). Cancer invasion and metastasis: molecular and cellular perspective. In Madame Curie Bioscience Database [Internet]. Landes Bioscience.
5. Greaves, M. F. (2001). Cancer: the evolutionary legacy. Oxford University Press.
6. Huxley J. Biological Aspects of Cancer. London: Allen and Unwin, 1958.
7. Hajdu, S. I. (2004). Greco‐Roman thought about cancer. Cancer: Interdisciplinary International Journal of the American Cancer Society, 100(10), 2048-2051.
8. Di Lonardo, A., Nasi, S., & Pulciani, S. (2015). Cancer: we should not forget the past. Journal of cancer, 6(1), 29.
9. Cooper, G. M. (1992). Elements of human cancer. Jones & Bartlett Learning.
10. Patel, A. (2020). Benign vs malignant tumors. JAMA oncology, 6(9), 1488-1488.
11. Fares, J., Fares, M. Y., Khachfe, H. H., Salhab, H. A., & Fares, Y. (2020). Molecular principles of metastasis: a hallmark of cancer revisited. Signal transduction and targeted therapy, 5(1), 28.
12. Mendoza, P. R., Specht, C. S., Hubbard, G. B., Wells, J. R., Lynn, M. J., Zhang, Q., ... & Grossniklaus, H. E. (2015). Histopathologic grading of anaplasia in retinoblastoma. American journal of ophthalmology, 159(4), 764-776.
13. Jang, S. J., Gardner, J. M., & Ro, J. Y. (2011). Diagnostic approach and prognostic factors of cancers. Advances in anatomic pathology, 18(2), 165-172.
14. Kimberly M. Newkirk, Erin M. Brannick, Donna F. Kusewitt, Chapter 6 - Neoplasia and Tumor Biology1, Editor(s): James F. Zachary, Pathologic Basis of Veterinary Disease (Sixth Edition), Mosby, 2017, Pages 286-321.e1.
15. Baba, A. I., & Câtoi, C. (2007). Comparative oncology (pp. 87-407). Bucharest: Publishing House of the Romanian Academy.
16. Jang, S. J., Gardner, J. M., & Ro, J. Y. (2011). Diagnostic approach and prognostic factors of cancers. Advances in anatomic pathology, 18(2), 165-172.
17. Yan, W., Wistuba, I. I., Emmert-Buck, M. R., & Erickson, H. S. (2011). Squamous cell carcinoma–similarities and differences among anatomical sites. American journal of cancer research, 1(3), 275.
18. Yang, J., Ren, Z., Du, X., Hao, M., & Zhou, W. (2014). The role of mesenchymal stem/progenitor cells in sarcoma: update and dispute. Stem cell investigation, 1.
19. Damerell, V., Pepper, M. S., & Prince, S. (2021). Molecular mechanisms underpinning sarcomas and implications for current and future therapy. Signal transduction and targeted therapy, 6(1), 246.
20. Vodanovich, D. A., & Choong, P. F. (2018). Soft-tissue sarcomas. Indian journal of orthopaedics, 52, 35-44.
21. Chennamadhavuni A, Lyengar V, Mukkamalla SKR, et al. Leukemia. [Updated 2023 Jan 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan.
22. Vakiti A, Mewawalla P. Acute Myeloid Leukemia. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan.
23. Matasar, M. J., & Zelenetz, A. D. (2008). Overview of lymphoma diagnosis and management. Radiologic Clinics of North America, 46(2), 175-198.
24. Pileri, S. A., Ascani, S., Leoncini, L., Sabattini, E., Zinzani, P. L., Piccaluga, P. P., ... & Stein, H. (2002). Hodgkin's lymphoma: the pathologist's viewpoint. Journal of clinical pathology, 55(3), 162-176.
25. Sapkota S, Shaikh H. Non-Hodgkin Lymphoma. [Updated 2023 Feb 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan.
26. PDQ Adult Treatment Editorial Board. Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®): Patient Version. 2023 May 12. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002.
27. Purkayastha, A., Pathak, A., Sharma, N., Viswanath, S., & Dutta, V. (2016). Primitive neuroectodermal tumor of lungs in adults: a rare series of three cases treated with upfront chemo-radiation. Translational Lung Cancer Research, 5(3), 350.
28. M Sherif Said. "Pathology of True Malignant Mixed Tumor (Carcinosarcoma)". Medscape. Updated: Dec 01, 2015.
29. Nowell, P. C. (1976). The Clonal Evolution of Tumor Cell Populations: Acquired genetic lability permits stepwise selection of variant sublines and underlies tumor progression. Science, 194(4260), 23-28.
30. Axelrod, R., Axelrod, D. E., & Pienta, K. J. (2006). Evolution of cooperation among tumor cells. Proceedings of the National Academy of Sciences, 103(36), 13474-13479.
31. Fisher, R., Pusztai, L., & Swanton, C. (2013). Cancer heterogeneity: implications for targeted therapeutics. British journal of cancer, 108(3), 479-485.
32. Afify, S. M., & Seno, M. (2019). Conversion of stem cells to cancer stem cells: undercurrent of cancer initiation. Cancers, 11(3), 345.
33. Shipitsin, M., & Polyak, K. (2008). The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Laboratory investigation, 88(5), 459-463.
34. S.A. Bapat, Evolution of cancer stem cells, Seminars in Cancer Biology, Volume 17, Issue 3, 2007, Pages 204-213, ISSN 1044-579X.
35. Vlashi, E., & Pajonk, F. (2015, April). Cancer stem cells, cancer cell plasticity and radiation therapy. In Seminars in cancer biology (Vol. 31, pp. 28-35). Academic Press.
36. Shackleton, M., Quintana, E., Fearon, E. R., & Morrison, S. J. (2009). Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell, 138(5), 822-829.
37. Mercadante, A. A., & Kasi, A. (2022). Genetics, cancer cell cycle phases. In StatPearls [Internet]. StatPearls Publishing.
38. Shay, J. W., & Wright, W. E. (2011, December). Role of telomeres and telomerase in cancer. In Seminars in cancer biology (Vol. 21, No. 6, pp. 349-353). Academic Press.
39. Nishida, N., Yano, H., Nishida, T., Kamura, T., & Kojiro, M. (2006). Angiogenesis in cancer. Vascular health and risk management, 2(3), 213-219.
40. Martin, T. A., Ye, L., Sanders, A. J., Lane, J., & Jiang, W. G. (2013). Cancer invasion and metastasis: molecular and cellular perspective. In Madame Curie Bioscience Database [Internet]. Landes Bioscience.
41. Fernald, K., & Kurokawa, M. (2013). Evading apoptosis in cancer. Trends in cell biology, 23(12), 620-633.
42. Liberti, M. V., & Locasale, J. W. (2016). The Warburg effect: how does it benefit cancer cells?. Trends in biochemical sciences, 41(3), 211-218.
43. Beerenwinkel, N., Antal, T., Dingli, D., Traulsen, A., Kinzler, K. W., Velculescu, V. E., ... & Nowak, M. A. (2007). Genetic progression and the waiting time to cancer. PLoS computational biology, 3(11), e225.
44. Alhmoud, J. F., Woolley, J. F., Al Moustafa, A. E., & Mallei, M. I. (2021). DNA damage/repair management in cancers. Advances in Medical Biochemistry, Genomics, Physiology, and Pathology, 309-339.
45. Gonzalez, H., Hagerling, C., & Werb, Z. (2018). Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes & development, 32(19-20), 1267-1284.
46. Sever, R., & Brugge, J. S. (2015). Signal transduction in cancer. Cold Spring Harbor perspectives in medicine, 5(4).
47. Janku, F. (2014). Tumor heterogeneity in the clinic: is it a real problem?. Therapeutic advances in medical oncology, 6(2), 43-51.
48. Barnes, J. L., Zubair, M., John, K., Poirier, M. C., & Martin, F. L. (2018). Carcinogens and DNA damage. Biochemical Society Transactions, 46(5), 1213-1224.
49. Kumari, S., Sharma, S., Advani, D., Khosla, A., Kumar, P., & Ambasta, R. K. (2021). Unboxing the molecular modalities of mutagens in cancer. Environmental Science and Pollution Research, 1-49.
50. White, M. C., Holman, D. M., Boehm, J. E., Peipins, L. A., Grossman, M., & Henley, S. J. (2014). Age and cancer risk: a potentially modifiable relationship. American journal of preventive medicine, 46(3), S7-S15.
51. Alberts, B. (2002). Molecular biology of the cell 4th edition.
52. Weinberg, R. A. (1988). The genetic origins of human cancer. Cancer, 61(10), 1963-1968.
53. Botezatu, A., Iancu, I. V., Popa, O., Plesa, A., Manda, D., Huica, I., … Badiu, C. (2016). Mechanisms of Oncogene Activation. InTech. doi: 10.5772/61249
54. Herceg, Z., & Hainaut, P. (2007). Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis. Molecular oncology, 1(1), 26-41.
55. Pierotti MA, Sozzi G, Croce CM. Mechanisms of oncogene activation. In: Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker; 2003.
56. Rodenhuis S. ras and human tumors. Semin Cancer Biol. 1992 Aug;3(4):241-7. PMID: 1421168.
57. Jančík, S., Drábek, J., Radzioch, D., & Hajdúch, M. (2010). Clinical relevance of KRAS in human cancers. Journal of Biomedicine and Biotechnology, 2010.
58. Cook, J. H., Melloni, G. E., Gulhan, D. C., Park, P. J., & Haigis, K. M. (2021). The origins and genetic interactions of KRAS mutations are allele-and tissue-specific. Nature communications, 12(1), 1808.
59. Bagci, O., & Kurtgöz, S. (2015). Amplification of cellular oncogenes in solid tumors. North American journal of medical sciences, 7(8), 341.
60. Kang, Z. J., Liu, Y. F., Xu, L. Z., Long, Z. J., Huang, D., Yang, Y., ... & Liu, Q. (2016). The Philadelphia chromosome in leukemogenesis. Chinese journal of cancer, 35, 1-15.
61. Davis, M., Malcolm, S., & Rabbitts, T. H. (1984). Chromosome translocation can occur on either side of the c-myc oncogene in Burkitt lymphoma cells. Nature, 308(5956), 286-288.
62. Ranzani, M., Annunziato, S., Adams, D. J., & Montini, E. (2013). Cancer gene discovery: exploiting insertional mutagenesis. Molecular Cancer Research, 11(10), 1141-1158.
63. Melamed, A., Yaguchi, H., Miura, M., Witkover, A., Fitzgerald, T. W., Birney, E., & Bangham, C. R. (2018). The human leukemia virus HTLV-1 alters the structure and transcription of host chromatin in cis. Elife, 7, e36245.
64. Gschwind, A., Fischer, O. M., & Ullrich, A. (2004). The discovery of receptor tyrosine kinases: targets for cancer therapy. Nature Reviews Cancer, 4(5), 361-370.
65. Ascierto, P. A., Kirkwood, J. M., Grob, J. J., Simeone, E., Grimaldi, A. M., Maio, M., ... & Mozzillo, N. (2012). The role of BRAF V600 mutation in melanoma. Journal of translational medicine, 10, 1-9.
66. Summy, J. M., & Gallick, G. E. (2003). Src family kinases in tumor progression and metastasis. Cancer and metastasis reviews, 22, 337-358.
67. Yates, K. E., & Gasson, J. C. (1996). Role of c-Fes in normal and neoplastic hematopoiesis. Stem Cells, 14(1), 117-123.
68. Hsu, J. L., & Hung, M. C. (2016). The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer and Metastasis Reviews, 35, 575-588.
69. Arienti, C., Pignatta, S., & Tesei, A. (2019). Epidermal growth factor receptor family and its role in gastric cancer. Frontiers in oncology, 9, 1308.
70. Press, R. D., Misra, A., Gillaspy, G., Samols, D., & Goldthwait, D. A. (1989). Control of the expression of c-sis mRNA in human glioblastoma cells by phorbol ester and transforming growth factor β. Cancer research, 49(11), 2914-2920.
71. Bradley, R. S., & Brown, A. M. (1990). The proto‐oncogene int‐1 encodes a secreted protein associated with the extracellular matrix. The EMBO journal, 9(5), 1569-1575.
72. Kalra, N., & Kumar, V. (2004). c-Fos is a mediator of the c-myc-induced apoptotic signaling in serum-deprived hepatoma cells via the p38 mitogen-activated protein kinase pathway. Journal of Biological Chemistry, 279(24), 25313-25319.
73. Lee, E. Y., & Muller, W. J. (2010). Oncogenes and tumor suppressor genes. Cold Spring Harbor perspectives in biology, 2(10), a003236.
74. Deininger, P. (1999). Genetic instability in cancer: caretaker and gatekeeper genes. Ochsner Journal, 1(4), 206-209.
75. Velez, A. M. A., & Howard, M. S. (2015). Tumor-suppressor genes, cell cycle regulatory checkpoints, and the skin. North American Journal of Medical Sciences, 7(5), 176.
76. Ozaki, T., & Nakagawara, A. (2011). Role of p53 in cell death and human cancers. Cancers, 3(1), 994-1013.
77. Kuwana, T., King, L. E., Cosentino, K., Suess, J., Garcia-Saez, A. J., Gilmore, A. P., & Newmeyer, D. D. (2020). Mitochondrial residence of the apoptosis inducer BAX is more important than BAX oligomerization in promoting membrane permeabilization. Journal of Biological Chemistry, 295(6), 1623-1636.
78. Prakash, R., Zhang, Y., Feng, W., & Jasin, M. (2015). Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harbor perspectives in biology, 7(4), a016600.
79. Li, G. M. (2008). Mechanisms and functions of DNA mismatch repair. Cell research, 18(1), 85-98.
80. Bouyahya, A., Mechchate, H., Oumeslakht, L., Zeouk, I., Aboulaghras, S., Balahbib, A., ... & El Omari, N. (2022). The role of epigenetic modifications in human cancers and the use of natural compounds as epidrugs: Mechanistic pathways and pharmacodynamic actions. Biomolecules, 12(3), 367.
81. Mendonsa, A. M., Na, T. Y., & Gumbiner, B. M. (2018). E-cadherin in contact inhibition and cancer. Oncogene, 37(35), 4769-4780.
82. Gutmann, D. H., Sherman, L., Seftor, L., Haipek, C., Hoang Lu, K., & Hendrix, M. (1999). Increased expression of the NF2 tumor suppressor gene product, merlin, impairs cell motility, adhesion and spreading. Human molecular genetics, 8(2), 267-275.
83. Chalhoub, N., & Baker, S. J. (2009). PTEN and the PI3-kinase pathway in cancer. Annual Review of Pathology: Mechanisms of Disease, 4, 127-150.
84. Patel, S., Alam, A., Pant, R., & Chattopadhyay, S. (2019). Wnt signaling and its significance within the tumor microenvironment: novel therapeutic insights. Frontiers in immunology, 10, 2872.
85. Senturk, E., & Manfredi, J. J. (2013). p53 and cell cycle effects after DNA damage. p53 Protocols, 49-61.
86. Williams, A. B., & Schumacher, B. (2016). p53 in the DNA-damage-repair process. Cold Spring Harbor perspectives in medicine, 6(5).
87. Guha T, Malkin D. Inherited TP53 Mutations and the Li-Fraumeni Syndrome. Cold Spring Harb Perspect Med. 2017 Apr 3;7(4):a026187. doi: 10.1101/cshperspect.a026187. PMID: 28270529; PMCID: PMC5378014.
88. Ezhevsky, S. A., Ho, A., Becker-Hapak, M., Davis, P. K., & Dowdy, S. F. (2001). Differential regulation of retinoblastoma tumor suppressor protein by G1 cyclin-dependent kinase complexes in vivo. Molecular and cellular biology.
89. He, S., Cook, B. L., Deverman, B. E., Weihe, U., Zhang, F., Prachand, V., ... & Weintraub, S. J. (2000). E2F is required to prevent inappropriate S-phase entry of mammalian cells. Molecular and cellular biology, 20(1), 363-371.
90. Ruijtenberg, S., & van den Heuvel, S. (2016). Coordinating cell proliferation and differentiation: Antagonism between cell cycle regulators and cell type-specific gene expression. Cell cycle, 15(2), 196-212.
91. Mastrangelo, D., Loré, C., & Grasso, G. (2011). Retinoblastoma as an epigenetic disease: a proposal. J Cancer Ther, 2(03), 362.
92. Mehrgou, A., & Akouchekian, M. (2016). The importance of BRCA1 and BRCA2 genes mutations in breast cancer development. Medical journal of the Islamic Republic of Iran, 30, 369.
93. Welcsh, P. L., & King, M. C. (2001). BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Human molecular genetics, 10(7), 705-713.
94. Petrucelli, N., Daly, M. B., & Pal, T. (2022). BRCA1-and BRCA2-associated hereditary breast and ovarian cancer.
95. Zayas-Villanueva, O. A., Campos-Acevedo, L. D., Lugo-Trampe, J. D. J., Hernández-Barajas, D., González-Guerrero, J. F., Noriega-Iriondo, M. F., ... & Martínez-de-Villarreal, L. E. (2019). Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case–control study. BMC cancer, 19(1), 1-8.
96. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010 Jan;2(1):a001008. doi: 10.1101/cshperspect.a001008. PMID: 20182602; PMCID: PMC2827900.
97. Dimaras, H., Corson, T. W., Cobrinik, D., White, A., Zhao, J., Munier, F. L., ... & Gallie, B. L. (2015). Retinoblastoma (Primer). Nature Reviews: Disease Primers, 1(1).
98. Shibata, D., Reale, M. A., Lavin, P., Silverman, M., Fearon, E. R., Steele Jr, G., ... & Summerhayes, I. C. (1996). The DCC protein and prognosis in colorectal cancer. New England Journal of Medicine, 335(23), 1727-1732.
99. Karajannis, M. A., & Ferner, R. E. (2015). Neurofibromatosis-related tumors: emerging biology and therapies. Current opinion in pediatrics, 27(1), 26.
100. Zou, M., Al-Baradie, R. S., Al-Hindi, H., Farid, N. R., & Shi, Y. (2005). S100A4 (Mts1) gene overexpression is associated with invasion and metastasis of papillary thyroid carcinoma. British journal of cancer, 93(11), 1277-1284.
101. Bonadona, V., Bonaïti, B., Olschwang, S., Grandjouan, S., Huiart, L., Longy, M., ... & Bonaïti-Pellié, C. (2011). Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. Jama, 305(22), 2304-2310.
102. Chial, H. (2008). Tumor suppressor (TS) genes and the two-hit hypothesis. Nature Education, 1(1), 177.
103. van Zijl, F., Krupitza, G., & Mikulits, W. (2011). Initial steps of metastasis: cell invasion and endothelial transmigration. Mutation Research/Reviews in Mutation Research, 728(1-2), 23-34.
104. Morgan-Parkes, J. H. (1995). Metastases: mechanisms, pathways, and cascades. AJR. American journal of roentgenology, 164(5), 1075-1082.
105. Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020 Aug 17;30(16):R921-R925. doi: 10.1016/j.cub.2020.06.081. PMID: 32810447; PMCID: PMC8194051.
106. Whiteside, T. L. (2008). The tumor microenvironment and its role in promoting tumor growth. Oncogene, 27(45), 5904-5912.
107. Taylor, B. C., & Balko, J. M. (2022). Mechanisms of MHC-I downregulation and role in immunotherapy response. Frontiers in immunology, 13, 844866.
108. Elgundi, Z., Papanicolaou, M., Major, G., Cox, T. R., Melrose, J., Whitelock, J. M., & Farrugia, B. L. (2020). Cancer metastasis: the role of the extracellular matrix and the heparan sulfate proteoglycan perlecan. Frontiers in oncology, 9, 1482.
109. Henke, E., Nandigama, R., & Ergün, S. (2020). Extracellular matrix in the tumor microenvironment and its impact on cancer therapy. Frontiers in molecular biosciences, 6, 160.
110. Haris, M., Yadav, S. K., Rizwan, A., Singh, A., Wang, E., Hariharan, H., ... & Marincola, F. M. (2015). Molecular magnetic resonance imaging in cancer. Journal of translational medicine, 13, 1-16.
111. Sharma, S. (2009). Tumor markers in clinical practice: General principles and guidelines. Indian journal of medical and paediatric oncology, 30(01), 1-8.
112. Tikkinen, K. A., Dahm, P., Lytvyn, L., Heen, A. F., Vernooij, R. W., Siemieniuk, R. A., ... & Agoritsas, T. (2018). Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline. Bmj, 362.
113. Kankanala VL, Mukkamalla SKR. Carcinoembryonic Antigen. [Updated 2023 Jan 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
114. Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int. 2014;2014:852748. doi: 10.1155/2014/852748. Epub 2014 Sep 7. PMID: 25276427; PMCID: PMC4170925.
115. Mardis, E. R. (2019). The impact of next-generation sequencing on cancer genomics: from discovery to clinic. Cold Spring Harbor Perspectives in Medicine, 9(9).
116. Raj, G. V., Moreno, J. G., & Gomella, L. G. (1998). Utilization of polymerase chain reaction technology in the detection of solid tumors. Cancer: Interdisciplinary International Journal of the American Cancer Society, 82(8), 1419-1442.
117. Hu, L., Ru, K., Zhang, L., Huang, Y., Zhu, X., Liu, H., ... & Miao, W. (2014). Fluorescence in situ hybridization (FISH): an increasingly demanded tool for biomarker research and personalized medicine. Biomarker research, 2, 1-13.
118. Govindarajan, R., Duraiyan, J., Kaliyappan, K., & Palanisamy, M. (2012). Microarray and its applications. Journal of pharmacy & bioallied sciences, 4(Suppl 2), S310.
119. Khatami, F., & Tavangar, S. M. (2018). Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy. Journal of Diabetes & Metabolic Disorders, 17, 19-30.
120. Bagnyukova, T. V., Serebriiskii, I. G., Zhou, Y., Hopper-Borge, E. A., Golemis, E. A., & Astsaturov, I. (2010). Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?. Cancer biology & therapy, 10(9), 839-853.
121. Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017). Combination therapy in combating cancer. Oncotarget, 8(23), 38022.
122. Johnson-Arbor K, Dubey R. Doxorubicin. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK459232/>
123. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014 Oct 5;740:364-78. doi: 10.1016/j.ejphar.2014.07.025. Epub 2014 Jul 21. PMID: 25058905; PMCID: PMC4146684.
124. Weaver, B. A. (2014). How Taxol/paclitaxel kills cancer cells. Molecular biology of the cell, 25(18), 2677-2681.
125. Zhang N, Yin Y, Xu SJ, Chen WS. 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules. 2008 Aug 5;13(8):1551-69. doi: 10.3390/molecules13081551. PMID: 18794772; PMCID: PMC6244944.
126. Koźmiński, P., Halik, P. K., Chesori, R., & Gniazdowska, E. (2020). Overview of dual-acting drug methotrexate in different neurological diseases, autoimmune pathologies and cancers. International journal of molecular sciences, 21(10), 3483.
127. Masoud, V., & Pagès, G. (2017). Targeted therapies in breast cancer: New challenges to fight against resistance. World journal of clinical oncology, 8(2), 120.
128. Skowronek, J. (2017). Current status of brachytherapy in cancer treatment–short overview. Journal of contemporary brachytherapy, 9(6), 581-589.
129. Hinshaw, D. C., & Shevde, L. A. (2019). The tumor microenvironment innately modulates cancer progression. Cancer research, 79(18), 4557-4566.
130. Ventola CL. Cancer Immunotherapy, Part 1: Current Strategies and Agents. P T. 2017 Jun;42(6):375-383. PMID: 28579724; PMCID: PMC5440098.
131. Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., ... & Kulasinghe, A. (2022). Immune checkpoint inhibitors in cancer therapy. Current Oncology, 29(5), 3044-3060.
132. Sterner, R. C., & Sterner, R. M. (2021). CAR-T cell therapy: current limitations and potential strategies. Blood cancer journal, 11(4), 69.
133. Wang, X., & Rivière, I. (2016). Clinical manufacturing of CAR T cells: foundation of a promising therapy. Molecular Therapy-Oncolytics, 3.
134. Pan, K., Farrukh, H., Chittepu, V. C. S. R., Xu, H., Pan, C. X., & Zhu, Z. (2022). CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. Journal of Experimental & Clinical Cancer Research, 41(1), 1-21.
135. Maalej, K. M., Merhi, M., Inchakalody, V. P., Mestiri, S., Alam, M., Maccalli, C., ... & Dermime, S. (2023). CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Molecular Cancer, 22(1), 20.
136. Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, Kitui SK, Manyazewal T. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med. 2021 Aug 12;9:20503121211034366. doi: 10.1177/20503121211034366. PMID: 34408877; PMCID: PMC8366192.
137. Johnson, K. B., Wei, W. Q., Weeraratne, D., Frisse, M. E., Misulis, K., Rhee, K., ... & Snowdon, J. L. (2021). Precision medicine, AI, and the future of personalized health care. Clinical and translational science, 14(1), 86-93.
138. Khaddour, K., Hana, C. K., & Mewawalla, P. (2019). Hematopoietic stem cell transplantation.
139. Giralt, S., & Bishop, M. R. (2009). Principles and overview of allogeneic hematopoietic stem cell transplantation. Hematopoietic Stem Cell Transplantation, 1-21.
140. Xin-Zhu, C., Rong, G., Cong, Z., Jing, X., Hang, S., Hua, Y., ... & Jian-Ye, Z. (2022). A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing. Frontiers in Pharmacologi, 13, 1-10.
141. Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., ... & Shao, A. (2020). Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Frontiers in molecular biosciences, 7, 193.
142. Babu, A., Muralidharan, R., Amreddy, N., Mehta, M., Munshi, A., & Ramesh, R. (2016). Nanoparticles for siRNA-based gene silencing in tumor therapy. IEEE transactions on nanobioscience, 15(8), 849-863.
143. Saeed, M., Gao, J., Shi, Y., Lammers, T., & Yu, H. (2019). Engineering nanoparticles to reprogram the tumor immune microenvironment for improved cancer immunotherapy. Theranostics, 9(26), 7981.
144. Makwana, V., Karanjia, J., Haselhorst, T., Anoopkumar-Dukie, S., & Rudrawar, S. (2021). Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization. International Journal of Pharmaceutics, 593, 120117.
145. Ma P, Mumper RJ. Paclitaxel Nano-Delivery Systems: A Comprehensive Review. J Nanomed Nanotechnol. 2013 Feb 18;4(2):1000164. doi: 10.4172/2157-7439.1000164. PMID: 24163786; PMCID: PMC3806207.
146. Cremolini, C., Vitale, E., Rastaldo, R., & Giachino, C. (2021). Advanced nanotechnology for enhancing immune checkpoint blockade therapy. Nanomaterials, 11(3), 661.
147. Xu, Z., Hall, T. L., Vlaisavljevich, E., & Lee Jr, F. T. (2021). Histotripsy: the first noninvasive, non-ionizing, non-thermal ablation technique based on ultrasound. International Journal of Hyperthermia, 38(1), 561-575.